NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY
Multiple Myeloma, Version 2.2024
ShajiK.Kumar,MD1,*; NatalieS. Callander, MD2,*; KehindeAdekola, MD,MSCI3; LarryD.Anderson Jr,MD, PhD4;
MuhamedBaljevic, MD5; RachidBaz, MD6;Erica Campagnaro, MD7; JorgeJ.Castillo, MD8,*; CaitlinCostello, MD9;
ChristopherD’Angelo, MD10; SrinivasDevarakonda, MD11; NouraElsedawy,MD12;AlfredGarfall, MD13;
KellyGodby,MD14;JensHillengass,MD, PhD15; Leona Holmberg, MD,PhD16; MyoHtut,MD17;Carol AnnHuff,MD18;
MalinHultcrantz, MD,PhD19; YubinKang,MD20;Sarah Larson,MD21;Hans C.Lee,MD22;Michaela Liedtke, MD23;
Thomas Martin, MD24; JamesOmel,MD25;TimothyRobinson,MD, PhD26; Aaron Rosenberg, MD27;
DouglasSborov,MD, MSc28; MarkA.Schroeder,MD29;Daniel Sherbenou, MD,PhD30;AttayaSuvannasankha,MD31;
JasonValent, MD32; Asya NinaVarshavsky-Yanovsky,MD, PhD33; RashmiKumar, PhD34;and JennaSnedeker,MS,ASCP34
ABSTRACT
NCCNCATEGORIESOFEVIDENCEANDCONSENSUS
Category1:Baseduponhigh-levelevidence,thereisuniform
The treatment of relapsed/refractory multiple myeloma (MM) has NCCNconsensusthattheinterventionisappropriate.
evolvedtoincludeseveralnewoptions.Theseincludenewcombina- Category2A:Baseduponlower-levelevidence,thereisuniform
tions with second generation proteasome inhibitors (PI); second NCCNconsensusthattheinterventionisappropriate.
generationimmunomodulators,monoclonalantibodies,CARTcells, Category 2B: Based upon lower-level evidence, there is
bispecificantibodies,selinexor,venetoclax,andmanyothers.Most
NCCNconsensusthattheinterventionisappropriate.
patientswithMMundergoseveralcyclesofremissionsandrelapse,
Category3:Baseduponanylevelofevidence,thereismajor
andthereforeneedmultiplelinesofcombinationtherapies.Selecting
NCCNdisagreementthattheinterventionisappropriate.
treatmentoptionsforrelapsed/refractoryMMrequiresconsideration
of resistance status to specific classes, and patient-specific factors Allrecommendationsarecategory2Aunlessotherwisenoted.
such as age and other comorbidities should be considered. The
Clinicaltrials:NCCNbelievesthatthebestmanagementof
NCCNGuidelinesforMMprovideaframeworkonwhichtobasede-
anypatientwithcancerisinaclinicaltrial.Participationin
cisionsregardingworkup,treatment,andfollow-upofnewlydiagnosed
clinicaltrialsisespeciallyencouraged.
andpreviouslytreatedMM.Thismanuscriptoutlinestherecommenda-
tions from NCCN Guidelines for MM specific to relapsed/refractory
PLEASENOTE
disease.
The NCCN Clinical Practice Guidelines in Oncology (NCCN
JNatlComprCancNetw2023;21(12):1281–1301
Guidelines®)areastatementofevidenceandconsensusofthe
doi:10.6004/jnccn.2023.0061
authorsregardingtheirviewsofcurrentlyacceptedapproaches
totreatment.AnyclinicianseekingtoapplyorconsulttheNCCN
Guidelinesisexpectedtouseindependentmedicaljudgmentin
thecontextofindividualclinicalcircumstancestodetermineany
patient’scareortreatment.TheNationalComprehensiveCancer
Network®(NCCN®)makesnorepresentationsorwarrantiesof
1MayoClinicComprehensiveCancerCenter;2UniversityofWisconsinCarbone
any kind regarding their content, use, or application and dis-
CancerCenter;3RobertH.LurieComprehensiveCancerCenterofNorthwestern
claimsanyresponsibilityfortheirapplicationoruseinanyway.
University;4UTSouthwesternSimmonsComprehensiveCancerCenter;
5Vanderbilt-IngramCancerCenter;6MoffittCancerCenter;7Universityof The complete NCCN Guidelines for Multiple Myeloma are
MichiganRogelCancerCenter;8Dana-Farber/BrighamandWomen’sCancer
notprintedinthisissueofJNCCNbutcanbeaccessedon-
Center|MassGeneralCancerCenter;9UCSanDiegoMooresCancerCenter; lineatNCCN.org.
10Fred&PamelaBuffettCancerCenter;11TheOhioStateUniversity
©2023,NationalComprehensiveCancerNetwork®(NCCN®).
ComprehensiveCancerCenter-JamesCancerHospitalandSoloveResearch
Institute;12St.JudeChildren’sResearchHospital/TheUniversityofTennessee Allrightsreserved.TheNCCNGuidelinesandtheillustrations
HealthScienceCenter;13AbramsonCancerCenterattheUniversityof hereinmaynotbereproducedinanyformwithouttheexpress
Pennsylvania;14O’NealComprehensiveCancerCenteratUAB;15RoswellPark writtenpermissionofNCCN.
ComprehensiveCancerCenter;16FredHutchinsonCancerCenter;17Cityof
HopeNationalMedicalCenter;18TheSidneyKimmelComprehensiveCancer DisclosuresfortheNCCNMultipleMyelomaPanel
CenteratJohnsHopkins;19MemorialSloanKetteringCancerCenter;20Duke
AtthebeginningofeachNCCNGuidelinesPanelmeeting,
CancerInstitute;21UCLAJonssonComprehensiveCancerCenter;22The
panelmembersreviewallpotentialconflictsofinterest.
UniversityofTexasMDAndersonCancerCenter;23StanfordCancerInstitute;
NCCN,inkeepingwithitscommitmenttopublictransparency,
24UCSFHelenDillerFamilyComprehensiveCancerCenter;25PatientAdvocate;
publishesthesedisclosuresforpanelmembers,staff,and
26YaleCancerCenter/SmilowCancerHospital;27UCDavisComprehensive
NCCNitself.
CancerCenter;28HuntsmanCancerInstituteattheUniversityofUtah;29Siteman
CancerCenteratBarnes-JewishHospitalandWashingtonUniversitySchoolof IndividualdisclosuresfortheNCCNMultipleMyelomaPanel
Medicine;30UniversityofColoradoCancerCenter;31IndianaUniversityMelvin memberscanbefoundonpage1301.(Themostrecentver-
andBrenSimonComprehensiveCancerCenter;32CaseComprehensiveCancer sionoftheseguidelinesandaccompanyingdisclosuresare
Center/UniversityHospitalsSeidmanCancerCenterandClevelandClinic availableatNCCN.org.)
TaussigCancerInstitute;33FoxChaseCancerCenter;and34National
ComprehensiveCancerNetwork. Thecompleteandmostrecentversionoftheseguidelinesis
availablefreeofchargeatNCCN.org.
*DiscussionWritingCommitteeMember.
JNCCN.org | Volume21 Issue12 | December2023 1281

NCCNGUIDELINES® MultipleMyeloma, Version2.2024
Overview The therapeutic options for previously treated MM
Multiple myeloma (MM) is a malignant neoplasm of include systemic therapy; autologous hematopoietic cell
plasma cells that accumulate in the bone marrow, lead- transplantation (HCT) for eligible patients who did not
ingtobonedestructionandmarrowfailure.MMismost receive HCT as part of their initial treatment; or clinical
frequentlydiagnosedamongpeopleaged65to74years, trial. For those who underwent autologous HCT as part
withthemedianagebeing69years.1TheAmericanCan- ofinitialtreatmentandhadadurableresponseorstable
cer Society has estimated 35,730 new MM cases and an disease, consideration may be given to a second trans-
estimated 12,590 deaths in the United States in 2023.2 plantationatthetimeofrelapse/diseaseprogression.
TheNCCNMultipleMyelomaPanelmembershavedevel- Asageneralprinciple,iftherelapseoccursat.6months
opedguidelinesforthemanagementofvariousplasmacell after completion of the initial primary therapy, pa-
neoplasms including monoclonal gammopathy of clinical tients may be retreated with the same primary regi-
significance,solitaryplasmacytoma,smolderingmyeloma, men.This,however,doesnotapplytoHCTforwhicha
MM, polyneuropathy, organomegaly, Endocrinopathy, longer remission would be needed to justify another
monoclonalplasmacelldisorder,skinchangessyndrome, transplant.
systemic lightchainamyloidosis, and Waldenstro€mmac-
roglobulinemia.Thismanuscriptfocusesonlyonmanage- PreferredRegimensforPreviouslyTreatedMultiple
mentofrelapsed/refractoryMM.ForthecompleteNCCN Myeloma:After1to3PriorTherapies
GuidelinesforMultipleMyeloma,pleasevisitnccn.org. Forpatientswhoarestillsensitivetobortezomiband/or
lenalidomide, any of the regimens listed below may be
Therapy for Previously Treated MM appropriate. Since, however, bortezomib-containing or
Avarietyoftherapiesareavailableforpreviouslytreated lenalidomide-containing regimens are often givenas in-
or relapsed/refractory MM. The choice of appropriate ductiontherapy,anditislikelythatatrelapsethedisease
therapy fora specific patient depends on thecontext of is refractory to these agents, especially if relapse is well
clinical relapse such as prior treatment and duration of within6monthsofprimarytreatmentcompletion,other
response. combinationsarepreferred.
1282 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume21 Issue12 | December2023

MultipleMyeloma,Version2.2024 NCCNGUIDELINES®
TheNCCNMMPanelhasprovidedalistofregimens Isatuximab-irfc/Carfilzomib/Dexamethasone
for bortezomib-refractory and lenalidomide-refractory A prospective, randomized, open label, phase III study
diseaseafter1to3priortherapies. (IKEMA)examinedtheutilityofisatuximab/carfilzomib/
dexamethasone versus carfilzomib/dexamethasone in
PreferredRegimensforBortezomib-or 302 patients with relapsed/refractory MM who had re-
Lenalidomide-RefractoryDisease ceived1to3priorlinesoftherapy(median,2priorlines
oftherapy).Treatmentwascontinueduntildiseaseprogres-
Daratumumab/Carfilzomib/Dexamethasone
sionorunacceptabletoxicity,withtheprimaryendpointbe-
AphaseIb,open-label,nonrandomized,multicentertrial
firststudiedthisregimeninpatients(n582)withrelapsed ing PFS. Median PFS was 35.7 months in the isatuximab/
carfilzomib/dexamethasone group versus a median
or refractory MM. At a median follow-up of 16 months,
PFS of 19.15 months in the carfilzomib/dexamethasone
the overall response rate (ORR) was 84%. In the overall
group(HR,0.53;99%CI,0.32–0.89,P5.0007).Grade3or
treatment population, although the median progression-
higher treatment-related adverse events occurred in 77%
freesurvival(PFS)wasnotreached,the12-monthand
ofpatientsintheisatuximabgroupversus67%ofpatients
18-month PFS rates were 74% and 66%, respectively.3
inthecontrolgroup.6Basedonthisdata,theNCCNpanel
Inamulticenter,open-labelphaseIIItrial(CANDOR),
theadditionofdaratumumabtocarfilzomibplusdexa-
hasincludedisatuximab-irfc/carfilzomib/dexamethasone
as acategory1,preferred regimenoptionfor relapsed or
methasone showed deeper responses and improved
PFS.4 Thisresponsehas beenshownto be maintained refractoryMM.
with longer follow-up analyses of about 27 months.
PFS was 28.6 months in the daratumumab group ver- Carfilzomib/Pomalidomide/Dexamethasone
sus15.2monthsinthecarfilzomibalonegroup(hazard A phase II trial investigated carfilzomib/pomalidomide/
ratio[HR],0.59;95CI,0.45–0.78;P,.0001).5Basedonthe dexamethasone followed by continuous pomalidomide/
previouslyciteddataandtheFDAapproval,thepanelhas dexamethasone as second line therapy for relapsed/
includedthisregimenasacategory1,preferredoptionfor refractory MM in patients who experienced progression
patientswithrelapsedorrefractoryMM. during lenalidomide maintenance therapy. Patients who
JNCCN.org | Volume21 Issue12 | December2023 1283

NCCNGUIDELINES® MultipleMyeloma, Version2.2024
wereeligiblefortransplantandhadnotreceiveditprevi- trialsofpomalidomideanddaratumumab,exceptforin-
ouslyreceivedHCT.Onthisregimen,75%ofpatientshad creaseinneutropenia.8
a very good partial response (VGPR), and 37% displayed The open-label phase III APOLLO trial randomly as-
complete response (CR). At 40-months of follow up, the signedpatientswithrelapsed/refractorydiseaseandatleast
median PFS was 26 months for patients who received
onepreviouslineoftherapy(n5304)toreceivepomalido-
therapy with HCT, and 17 months for patients who re- mide/dexamethasone or daratumumab/pomalidomide/
ceived carfilzomib/pomalidomide/dexamethasone ther- dexamethasone. With a median follow up time of
apy without HCT. The median overall survival (OS) was 16.9months,astatisticallysignificant improvement
was seen in the primary endpoint of PFS for the added
67months,withthemostcommongrade3and4adverse
daratumumabgroup(12.4vs6.9months;P5.0018).Seri-
eventsrelatedtotreatmentincludinghematologictoxicity
ousadverseeventsoccurredin50%ofpatientsinthedar-
(41%),cardiovascular(6%)andrespiratory(3%)events,and
atumumab group compared with 39% of patients in the
infections(17%).7Basedonthesedata,theNCCNpanelhas
included carfilzomib/pomalidomide/dexamethasone as a pomalidomide/dexamethasonegroup,themostcommon
beingpneumoniaandlowerrespiratorytractinfections.9
preferredregimenoptionforrelapsedorrefractoryMM.
TheMM-014studyevaluated112patientswithrelapsed/
refractoryMMwhohadpreviouslybeentreatedwithlenalido-
Daratumumab/Pomalidomide/Dexamethasone
mideandassignedthemtoaregimencontainingdaratumu-
Thecombinationofdaratumumab/pomalidomide/dexa- mab/pomalidomide/dexamethasone.Theprimaryendpoint
methasone was evaluated in an open-label, multicenter, wasORR,whichwasachievedin77.7%ofpatientsiname-
phaseIbstudy(MMY1001).Thisstudyincludedpatients dianfollowupof17.2months(medianPFSwasnotreached
(n5103 patients) who had received at least 2 prior lines at time of follow up). The most common adverse event of
of therapy (excluding daratumumab or pomalidomide).8 grade3orhigherwasinfection,whichdevelopedin31.3%of
Atamedianfollow-upof13.1months,theORRwas60%. patients(13.4%withgrade3orhigherpneumonia).10
The median PFS and OS were 8.8 and 17.5 months, re- Basedonthepreviouslyciteddata,theNCCNpanel
spectively, and estimated survival at 1 year was 66%.8 has included daratumumab/pomalidomide/dexametha-
Toxicities reported were similar to those seen in other sone as a treatment option for patients with relapsed/
1284 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume21 Issue12 | December2023

MultipleMyeloma,Version2.2024 NCCNGUIDELINES®
refractory MM who have received one prior therapy in- patientshavingaPRorbetter,amedianPFSof4.4months,
cludinganimmunomodulator(IMiD)andaproteasome amedianresponsedurationof16.8months,andamedian
inhibitor(PI). OSof34.3months.Commonadverseeventsincludedhe-
matologictoxicity,andgastrointestinalevents.13
Isatuximab-irfc/pomalidomide/dexamethasone Another phase I/II study examined the safety and effi-
Inanopen-label,multicenter,phaseIIItrial(ICARIA-MM), cacyofixazomib/pomalidomide/dexamethasoneinpatients
patients(n5307)withMMwhohadreceivedatleast2lines whohadmultiplepriortherapies,wererefractorytolenalido-
ofpriortherapy,includinglenalidomideandaPIwereran- midealone,orwererefractorytolenalidomideandbortezo-
domizedtoreceivepomalidomide/dexamethasonewithor mib, or lenalidomide, bortezomib, and carfilzomib.14 The
without isatuximab-irfc.11 After a median follow-up of ORRswere33%and40%with2differentdosesofixazomib.14
12months,ahigherORR(60%vs35%)andimprovedPFS Considering promising preliminary response rates,
(median, 11.5 vs 6.5 months; HR, 0.6; 95% CI, 0.44–0.81) especially in patients whose disease was refractory to
were reported in the isatuximab-irfc/pomalidomide/ bothlenalidomideandaPI,theNCCNPanelhasincluded
dexamethasonearm.Inaprespecifiedsubgroupanalysis ixazomib/pomalidomide/dexamethasone as a treatment
of this study, the addition of isatuximab-irfc showed im- option for patients with relapsed/refractory MM who
provedORRandPFSinpatientswithrenalimpairment.12 havereceivedatleast2priortherapiesincludinganIMiD
The NCCN MM Panel has included isatuximab-irfc/ andaPIandhaveshowndiseaseprogressiononorwithin
pomalidomide/dexamethasone as a category 1, preferred 60daysofcompletionofthelasttherapy.
optionforthetreatmentofpatientswithrelapsed/refractory
MMafter2priortherapiesincludinglenalidomideandaPI. AdditionalPreferredRegimensfor
Bortezomib-RefractoryDisease
Ixazomib/Pomalidomide/Dexamethasone Inadditiontotheregimenslistedintheprevioussection,
InthephaseI/IIAllianceA061202study(n529),patients thefollowing2lenalidomide-containingregimensmaybe
withlenalidomide/PIrefractoryMMweretreatedwith usedforlenalidomide-sensitiveornaïveandbortezomib-
ixazomib/pomalidomide/dexamethasone- with 51.7% of refractorydisease.
JNCCN.org | Volume21 Issue12 | December2023 1285

NCCNGUIDELINES® MultipleMyeloma, Version2.2024
Daratumumab/Lenalidomide/Dexamethasone subgroup of patients with one prior line of therapy, the
Inamulticenter,open-labelphaseIIItrial(POLLUX),patients median PFS was 27.0 months with daratumumab versus
(n5569) with relapsed/refractory MM were randomized to 7.9 months with daratumumab and lenalidomide (HR,
receivelenalidomide/dexamethasonewithorwithoutdaratu- 0.22; 95% CI, 0.15–0.32; P,.0001). The ORR rates for pa-
mumabuntildiseaseprogressionorunacceptabletoxicity.15 tientswithonepriorlineoftherapyforthosereceivingthe
Afteramedianfollow-upof13.5months,daratumu- daratumumab-regimen was 92% compared with 74% in
mab in combination with lenalidomideand dexametha- thosereceivingdaratumumab/dexamethasone.16
sonewasassociatedwithbetterPFSandORRcompared Based on the above data, the NCCN MM Panel has
withlenalidomide/dexamethasonealone.Afteramedian added daratumumab/lenalidomide/dexamethasone as a
follow-upof25.4months,asubsequentanalysisreported category1,preferredoptionforthetreatmentofpatients
that the higher ORR (92.9% vs 76.4%, P,.001), and PFS withrelapsed/refractoryMM.
(83%vs60%at12months;68%vs41%at24months;HR,
0.41; 95% CI, 0.31–0.53) was maintained in those who Carfilzomib/Lenalidomide/Dexamethasone
hadreceiveddaratumumab.15 The randomized, multicenter, phase III ASPIRE trial,
Themostcommonadverseeventsofgrade3or4in studiedthecombinationoflenalidomideanddexameth-
patients treated with the daratumumab regimen versus asone with or without carfilzomib in patients (n5792)
lenalidomide/dexamethasone were neutropenia (51.9% with relapsed/refractory MM who had received 1 to 3
vs 37.0%), thrombocytopenia (12.7% vs 13.5%), and ane- priorlinesoftherapy.Theprimaryendpointofthestudy
mia(12.4%vs19.6%).Daratumumab-associatedinfusion- wasPFS.Theresultsshowedthattheadditionofcarfilzo-
related reactions (mostly grade 1 or 2) were reported in mibtolenalidomideanddexamethasonesignificantlyim-
47.7%ofpatients. provedPFSby8.7months(26.3monthsforthecarfilzomib
Withanextendedfollow-upof3.5years,theimprove- arm vs 17.6 months for lenalidomide and low-dose dexa-
mentsinPFSandORRcontinuedtobemaintainedinpa- methasone; HR for progression or death, 0.69; 95% CI,
tientstreatedwiththedaratumumabregimen(PFS,16.7vs 0.57–0.83; P5.0001). The median duration of treatment
7.1 months; HR, 0.31; 95%; CI, 0.25–0.40; P,.0001). In a waslongerinthecarfilzomibgroup(88.0vs57weeks).The
1286 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume21 Issue12 | December2023

MultipleMyeloma,Version2.2024 NCCNGUIDELINES®
incidenceof peripheralneuropathywas nearly identical for patients with recurrent/refractory MM.18 Patients
in both arms (17%). Nonhematologic adverse effects (n5498) were randomized to receive daratumumab/
($grade3)thatwerehigherinthecarfilzomibgroupcom- bortezomib/dexamethasone or bortezomib/dexametha-
pared with lenalidomide and dexamethasone included sone.TheORRinthedaratumumabarmwas82.9%com-
dyspnea(2.8%vs1.8%),cardiacfailure(3.8%vs1.8%),and paredwith63.2%inthecontrolarm(P,.001).18Therates
hypertension(4.3%vs1.8%).Therewerefewerdiscontinu- of VGPR and CR were double in the daratumumab arm
ationsduetosideeffectsinthecarfilzomibarm(15.3%vs comparedwiththecontrolarm(59.2%vs29.1%;P,.001
17.7%). Patients in the carfilzomib arm reported superior and 19.2% vs 9.0%; P5.001, respectively). The 12-month
health-relatedqualityoflifethanthosewhoreceivedlena- estimatedrateofPFSwassignificantlyhigherinthedara-
lidomideanddexamethasonealone.17
tumumabarmcomparedwiththecontrolarm(60.7%vs
Based onthe previously stated data,the NCCNMM 26.9%).18 The most common grade 3 or 4 adverse events
Panel has included the combination of carfilzomib with
reported in the daratumumab and control groups were
lenalidomide and dexamethasone as a category 1, pre-
thrombocytopenia (45.3% and 32.9%, respectively), ane-
ferredoptionforpatientswithrelapsed/refractoryMM.
mia (14.4% and 16.0%, respectively), and neutropenia
(12.8% and 4.2%, respectively).18 Grade 1 or 2 infusion-
AdditionalPreferredRegimensfor
related reactions associated with daratumumab were re-
Lenalidomide-RefractoryDisease
ported in 45.3% of the patients in the daratumumab
In addition to the regimens listed in the section for
groupandgrade3in8.6%ofthepatients.Theseinfusion-
bortezomib-andlenalidomiderefractorydisease,thefol-
related reaction rates are consistent with findings from
lowing bortezomib-containing regimens may be used for
previoustrialsofdaratumumab.19,20
bortezomib-sensitiveor-naïveandlenalidomide-refractory
After a median follow-up of 40months, patients re-
disease.
ceiving the daratumumab containing regimen demon-
Daratumumab/Bortezomib/Dexamethasone strateda69%reductionintheriskofdiseaseprogression
AphaseIIItrialshowedthataddingdaratumumabtobor- ordeath(medianPFS,16.7 vs7.1months;HR,0.31;95%
tezomibanddexamethasonemarkedlyimprovedoutcomes CI, 0.25–0.40; P,.0001), and showed significantly better
JNCCN.org | Volume21 Issue12 | December2023 1287

NCCNGUIDELINES® MultipleMyeloma, Version2.2024
ORR(85%vs63%;P,.0001).21Patientswhoreceivedone exposure,andpriorHCT.Statisticallysignificantimprove-
priorlineoftherapydemonstratedthegreatestbenefitwith ments in PFS were seen in both lenalidomide-refractory
daratumumab (median PFS, 27.0 vs 7.9months; HR, 0.22; (17.8 vs 9.5 months; P5.0276) and lenalidomide–
95%CI,0.15–0.32;P,.0001). nonrefractory(22.0 vs 12.0 months; P5.0491) patients.
Based on the previously noted phase III data, the StatisticallysignificantimprovementsinPFSwerealso
NCCN Panel has added daratumumab/bortezomib/ seeninpatientswhohadreceivedpriorbortezomib(17.8vs
dexamethasone as a category 1, preferred option for the 12 months), and patients with (22 vs 13.8 months) and
treatmentofpatientswithrelapsed/refractoryMM. without(16.5vs9.5months)priorHCT.23
Basedonthesedata,theNCCNGuidelinesPanelhas
Pomalidomide/Bortezomib/Dexamethasone included pomalidomide/bortezomib/dexamethasone as a
A phase III open-label, multicenter, randomized, trial category 1, preferred option for the treatment of patients
(OPTIMISMM) evaluated pomalidomide/bortezomib/ withrelapsed/refractoryMM.
dexamethasone (n5281) versus bortezomib/dexametha-
sone in patients (n5278) with relapsed or refractory MM Selinexor/Bortezomib/Dexamethasone
who previously received lenalidomide.22 After a median AnongoingphaseIII,randomizedopenlabeltrial(BOSTON)
follow-up of 15.9 months, a significantly improved PFS compared selinexor/bortezomib/dexamethasone with
was seen in the pomalidomide arm (median, 11.20 vs bortezomib/dexamethasone in patients with previously
7.10months;HR,0.61;95%CI,0.49–0.77;P,.0001).The treated MM (1–3 prior lines of therapy, including PIs).
most common grade 3/4 treatment-related adverse Four hundred two patients were randomized to the seli-
events in the pomalidomide arm reported in this trial nexor/bortezomib/dexamethasoneand206tothebortez-
wereneutropenia,infections,andthrombocytopenia.22A omib/dexamethasone group. After a median follow-up
posthocsubgroupanalysisoftheOPTIMISSMtrialevalu- duration of 13.2 months in the selinexor/bortezomib/
atedoutcomesin226patientsatfirstrelapsethathadonly dexamethasonegroup,themedianPFSwas13.93months
received one prior line of therapy. Analyses were con- comparedwithamedianfollowupdurationof16.5months
ductedbylenalidomide-refractorystatus,priorbortezomib and median PFS of 9.46 months in the bortezomib/
1288 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume21 Issue12 | December2023

MultipleMyeloma,Version2.2024 NCCNGUIDELINES®
dexamethasone group (HR, 0.70; 95% CI, 0.53–0.93; (16%vs10%),dyspnea(6%vs2%),decreasedlymphocyte
P5.0075).Themostfrequentadverseeventsofgrade3–4 count (6% vs 2%), diarrhea (4% vs 9%), and peripheral
that were more common in the selinexor/bortezomib/ neuropathy (1% vs 6%).28 Rates of thrombocytopenia,
dexamethasone group were thrombocytopenia (39% vs pneumonia,andfatigueweresimilarinbothgroups.28
17%),fatigue(13%vs1%),andanemia(16%vs10%).24 BasedonthesephaseIIIdata,theNCCNMMGuide-
Basedonthepreviouslyciteddata,theNCCNGuide- lines Panel has included the combination of carfilzomib
linesPanelhasincludedonceweeklyselinexorincombina- (twice weekly) and dexamethasone as a category 1, pre-
tionwithbortezomibanddexamethasoneasacategory1, ferredoptionforpatientswithrelapsed/refractoryMM.
other recommended regimen option for previously
treatedMM. Elotuzumab/Lenalidomide/Dexamethasone
TheFDAhasapprovedelotuzumabincombinationwith
Elotuzumab/Pomalidomide/Dexamethasone lenalidomide and dexamethasone for the treatment of
In a phase II study, patients (n5117) with refractory/
patientswithMMwhohavereceived1to3priorthera-
relapsed MM and refractory to lenalidomide and a PI
pies. This is based on the results of the phase III trial,
were randomized to receive pomalidomide/dexametha-
ELOQUENT-2. The trial randomized 646 patients (1:1)
soneorelotuzumab/pomalidomide/dexamethasone.25 Af-
to receive either elotuzumab in combination with lenali-
ter a follow-up of 9.1 months, the median PFS and ORR
domide and dexamethasone or lenalidomide and dexa-
were both more than double with elotuzumab (PFS, 10.3
methasonealone.29
vs 4.7 months; ORR, 53% vs 26%).25 Median OS was also
The rates of PFS at the end of 1 and 2 years were
significantly improved with elotuzumab/pomalidomide/
higher for those receiving the elotuzumab-containing
dexamethasonecomparedwithpomalidomide/dexameth-
regimen (68% at 1 year and 41% at 2 years) compared
asone (29.8 vs 17.4 months; HR, 0.59; 95% CI, 0.37–0.93;
with those receiving lenalidomide and dexamethasone
P5.0217).26
alone(57%at1yearand27%at2years).29MedianPFSin
TheNCCNGuidelinesPanelhasincludedthecombi-
the group receiving the elotuzumab-containing regimen
nationofpomalidomide/dexamethasone/elotuzumabas
was 19.4 months versus 14.9 months in those receiving
anoptionforpatientswhohavereceived$2priorthera-
lenalidomideanddexamethasonealone(HRforprogres-
piesincludinganIMiDandaPI.
sion or death in the elotuzumab group, 0.70; 95% CI,
0.57–0.85;P,.001)indicatingarelativereductionof30%
OtherRecommendedRegimensforRelapseAfter
in the risk of disease progression or death.29 Common
OnetoThreePriorTherapies
grade3or4adverseeventsinbotharmsofthetrialwere
Carfilzomib(TwiceWeekly)/Dexamethasone lymphocytopenia,neutropenia,fatigue,andpneumonia.
The results of the phase III ENDEAVOR trial in patients Infusion reactions occurred in 33 patients (10%) in the
with relapsed/refractory MM treated with multiple prior elotuzumabgroupandweregrade1or2in29patients.29
linesoftherapyshoweda2-foldimprovementinmedian Consistent with these findings, a subset analysis of 3-
PFS with carfilzomib/dexamethasone compared with yearfollow-upreportedareducedriskofprogressionby27%
bortezomib/dexamethasone (18.7 vs 9.4 months; HR, withtheelotuzumab/lenalidomide/dexamethasonecom-
0.53; P,.0001).27 ORR was 77% inthe carfilzomib group binationcomparedwithlenalidomide/dexamethasone.30
versus63%inthebortezomibgroup;ratesofCRorbetter The final results of the ELOQUENT-2 study have
were13%and6%andratesofVGPRwere42%and22%, demonstratedthat the addition of elotuzumab to lenali-
respectively. The median duration of response was domide/dexamethasone improved OS in patients with
21.3monthsinthecarfilzomibgroupand10.4monthsin
MM who received 1 to 3 prior lines of therapy (48.3 vs
the bortezomib group. Adverse events (grade 3 or higher) 39.6months).31
inthecarfilzomibarmcomparedwiththebortezomibarm
BasedontheabovedataandFDAapprovaltheNCCN
included hypertension (6% vs 3%), anemia (12% vs 9%), Panelhasincludedelotuzumabincombinationwithlena-
thrombocytopenia(10%vs14%),anddyspnea(5%vs2%). lidomide and dexamethasone as a category 1 option for
Rateofgrade$2peripheralneuropathywas6%inthecar-
previouslytreatedMM.
filzomibgroupand32%inthebortezomibgroup.27
TheOSanalysisshowedthatthosetreatedwithcarfil- Ixazomib/Lenalidomide/Dexamethasone
zomib/dexamethasone lived 7.6 months longer (median A double-blind, randomized, placebo-controlled, phase
OSwas47.6monthsinthecarfilzomibgroupvs40months III TOURMALINE MM1 trial randomized 722 patients
inthebortezomibgroup;HR,0.791[95%CI,0.648–0.964]; withrelapsedand/orrefractoryMMtoacombinationof
P5.010).28 The most frequent grade 3 or worse adverse ixazomibpluslenalidomideanddexamethasoneorlena-
eventsinthecarfilzomibarmcomparedwiththebortezo- lidomideanddexamethasonealone(controlgroup).This
mib arm included hypertension (15% vs 3%), anemia trial was designed based on the promising results of a
JNCCN.org | Volume21 Issue12 | December2023 1289

NCCNGUIDELINES® MultipleMyeloma, Version2.2024
phase I/II study (discussed under “Other Recommended OS was 30 months (95% CI, 24–37).37 The NCCN MM
Primary Therapy Regimens for Transplant Candidates,” Panel members have included bortezomib/lenalido-
availableonline,intheseNCCNGuidelines,atNCCN.org).32 mide/dexamethasone as other recommended regimen
The results of the TOURMALINE MM1 trial show a forrelapsed/refractoryMMafter1to3priortherapies.
significant improvement in PFS with the ixazomib-
Carfilzomib/Cyclophosphamide/Dexamethasone
containing regimen. After a median follow-up of almost
Carfilzomib/cyclophosphamide/dexamethasone has been
15 months, a 35% improvement in PFS was seen in the
showntobewelltoleratedwiththetoxicityprofileofcarfil-
grouptreatedwiththeixazomibregimencomparedwith
zomibbeingsimilartothatseeninothertrials.38
the control group (HR, 0.74; P5.01).33 Median PFS was
A phase II trial (MUKfive) compared the safety and
20.6 months in the ixazomib-treated group versus
toxicityofcarfilzomib/cyclophosphamide/dexamethasone
14.7 months in the group receiving lenalidomide and
with bortezomib/cyclophosphamide/dexamethasone in
dexamethasone alone. In the ixazomib-treated group
patients with relapsed/refractory MM, who had received
versusthecontrolgroup,theORR(78%vs72%,P5.035)
onepriorregimen.38Ahigherproportionofpatientsreceiv-
and CR (11.7% vs 6.6%, P5.019) werealso improved.Of
ing carfilzomib experienced VGPR or better, and it was
note,patientswithhigh-riskcytogeneticsenrolledinthe
noninferiortobortezomib.Carfilzomib/cyclophosphamide/
trial receiving ixazomib had a similar HR for PFS as the
dexamethasonewaswelltolerated,withthetoxicityprofile
entire study population (HR, 0.596 and 0.543, respec-
of carfilzomib being similar to that seen in other trials.38
tively).33 Grade $3 adverse events were reported in 74%
Thisstudyalsoincludedamaintenancephaseanddemon-
and 69%ofpatients intheixazomib-treatedand control
stratedamedianPFSof11.9versus5.6monthsinfavorof
groups, respectively. These included anemia (9% with
carfilzomibmaintenanceversusobservation.
ixazomib/lenalidomide/dexamethasone vs 13% with le-
Another phase II trial compared treatment with cy-
nalidomide/dexamethasone), thrombocytopenia (19% vs clophosphamidepluscarfilzomibanddexamethasoneto
9%), and neutropenia (23% vs 24%).33 The addition of treatment with carfilzomib and dexamethasone in pa-
theixazomib/lenalidomide/dexamethasonegrouphad tients (n5197) with relapsed/refractory MM after 1 to 3
a slightly higher rate of peripheral neuropathy compared
priorlines.39Afteramedianfollow-upof37months,me-
withlenalidomide/dexamethasone(27%vs22%).
dian PFS was 19.1 with the 3-drug regimen compared
Based on the results of the phase III TOURMALINE with 16.6 months with the 2-drug regimen (P5.577).39
MM1trial33thepanelhasincludedixazomib/lenalidomide/
The combination of cyclophosphamide with carfilzomib
dexamethasone as a category 1, preferred regimen option and dexamethasone did not improve outcomes signifi-
forpreviouslytreatedMMafter1to3priortherapies. cantly compared with carfilzomib and dexamethasone
alone in the overall population. However, in a subgroup
Bortezomib/Cyclophosphamide/Dexamethasone
analysisofthelenalidomide-refractorypopulation,thead-
The effects of adding an alkylating agent (such as cyclo-
ditionofcyclophosphamidetocarfilzomibanddexameth-
phosphamide) and a novel agent (such as lenalidomide
asoneresultedinaPFSbenefitof18.4versus11.3months
orbortezomib)todexamethasonehavebeeninvestigated
(HR,1.7;95%CI,1.1–2.7;P5.043).39
for patients with relapsed/refractoryMM.The combina-
Thepanelhasincludedcarfilzomib/cyclophosphamide/
tion of bortezomib, dexamethasone, and cyclophospha-
dexamethasoneastreatmentasanotherrecommendedregi-
midewasfoundtobeeffectiveinpatientswithrelapsed/
refractoryMMwithanacceptabletoxicityprofile.34,35The menforrelapsed/refractoryMMafter1to3priortherapies.
NCCN MM Panel members have included bortezomib/ Daratumumab/Cyclophosphamide/Bortezomib/
cyclophosphamide/dexamethasone as an other recom- Dexamethasone
mendedregimenforrelapsed/refractoryMMafter1to3 In the LYRA study,40 among the small cohort of patients
priortherapies. withrelapsedMM(n514),after4cyclesofinductionther-
apy,ORRwas12.3%andVGPRorbetterwasseenin57.1%
Bortezomib/Lenalidomide/Dexamethasone
ofpatients.40TheORRafter4inductioncycleswas71.4%.
Datafrompreclinicalstudiesshowedlenalidomidesensitizes
The median PFS was 13.3 months (95% CI, 6.8–13.3). At
myeloma cells to bortezomib and dexamethasone. The re-
12-months,theOSratewas54.5%(95%CI,8.6%–86.1%).40
sultsofphaseIandphaseIIstudiesshowthatbortezomib/
Basedonthis,theNCCNGuidelinesPanelhasincluded
lenalidomide/dexamethasone is well tolerated and ac-
daratumumab/bortezomib/cyclophosphamide/dexametha-
tive, with durable responses in heavily pretreated pa-
soneasatreatmentoptionforrelapsed/refractoryMM.
tients with relapsed and/or refractory MM, including
patients who have had prior lenalidomide, bortezomib, Elotuzumab/Bortezomib/Dexamethasone
thalidomide, and HCT.36,37 After a median follow-up of Numerous randomized trials have shown that 3-drug
44months,themedianPFSwas9.5monthsandmedian combinationsareconsistentlymoreeffectivethan2-drug
1290 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume21 Issue12 | December2023

MultipleMyeloma,Version2.2024 NCCNGUIDELINES®
combinations for the treatment of MM. A phase II thrombocytopenia,respectively,werereportedin11%,
trial studied the effect of theaddition ofelotuzumab to 31%, and 6% of patients treated with pomalidomide/
bortezomib/dexamethasone in patients with relapsed/ dexamethasoneand24%,52%,and15%ofpatientstreated
refractoryMM.41 withthetripletregimen.46Similarresultswerereportedby
Interim analysis results showed a 28% reduction in asingle-centerretrospectivestudyofpatients(n520)with
risk of disease progression or death for patients in the relapsed/refractory MM who received pomalidomide/
elotuzumab-containing triple-drug arm compared with cyclophosphamide/dexamethasoneuntiltransplantor
patientstreatedwithbortezomib/dexamethasone(HR,0.72; disease.47 Response to the triple-drug regimen was 63%,
70% CI,0.59–0.88).MedianPFSwas significantly higher in withnearlyhalfofpatients(42%)after1cyclewithame-
the elotuzumab-containing arm (9.7 vs 6.9 months). After dian time to response of 3 cycles. One-year median PFS
2 years the addition of elotuzumab continued to show an was80.7%,and65%ofpatientswererelapse-free.47
efficacybenefitcomparedwithbortezomib/dexamethasone BasedonthesephaseIItrialdata,theNCCNGuide-
alone with a 24% relative risk reduction in PFS (HR, 0.76; lines Panel has included pomalidomide/cyclophospha-
70%CI,0.63–0.91).41 mide/dexamethasone as other recommended treatment
Based on these phase II trial data, the panel has option for patients with relapsed/refractory MM who
included elotuzumab/bortezomib/dexamethasone as an havereceived2priortherapies,includinganIMiDanda
otherrecommendedregimenforrelapsed/refractoryMM PIanddiseaseprogressionon/within60daysofcomple-
after1to3priortherapies. tionoflasttherapy.
Ixazomib/Cyclophosphamide/Dexamethasone RegimensUsefulinCertainCircumstancesfor
This regimen has beenshown to be tolerable and effica- PreviouslyTreatedMM–EarlyRelapse
cious in newly diagnosed patients.42,43 A phase II study (1to3PriorTherapies)
evaluated this regimen in the relapsed/refractory setting
Bortezomib/LiposomalDoxorubicin/Dexamethasone
inpatientswithamedianageof63.5yearsandfoundthat
Bortezomib with liposomal doxorubicin (PLD) was ap-
itiswelltolerated.Atamedianfollow-upof15.2months
proved by the FDA as a treatment option for patients
in the phase II study, median PFS was 14.2 months. The
with MM who have not previously received bortezomib
PFStrendwiththisregimenwasbetterinpatientsaged65
and have received at least one prior therapy. The ap-
and older compared with those younger than 65 years
(median, 18.7 vs 12.0 months; HR 0.62; P5.14).44 The provalwasbasedonapriorityreviewofdatafromanin-
ternational phase III trial (n5646) showing that use of
NCCNGuidelinesPanelhasincludedthisalloralregimen
under the list of “other recommended regimens” for the combination significantlyextended themediantime
to disease progression compared with bortezomib alone
relapsed/refractoryMM.
(9.3 vs 6.5 months).48 Median duration of response was
Lenalidomide/Cyclophosphamide/Dexamethasone increasedfrom7.0to10.2monthswiththecombination
A retrospective analysis to assess the efficacy of lenalido- therapy. Based on these results, the NCCN MM Panel
mide in combination with cyclophosphamide and dexa- considers bortezomib with the PLD regimen as a cate-
methasoneshowedthatthisregimeniseffectiveinheavily gory 1 option that is useful in certain circumstances for
pretreatedpatientswithmanageableadverseeffects.45The patientswithrelapsed/refractoryMM.
NCCNGuidelinesPanelhasincludedcyclophosphamide/
Bortezomib/Dexamethasone
lenalidomide/dexamethasone treatment as an other rec-
The addition of dexamethasone to bortezomib in pa-
ommendedregimenforrelapsed/refractoryMMafter1to
tients with relapsed/refractory MM who had PD during
3priortherapies.
bortezomibmonotherapyresultedinimprovementofre-
sponse in 18%–34% of patients.49–51 The NCCN MM
Pomalidomide/Cyclophosphamide/Dexamethasone
Panelmembershaveincludedthebortezomibanddexa-
AphaseIIstudycomparedthecombinationofpomalido-
methasoneregimenasanoptionthatisusefulincertain
mide/cyclophosphamide/dexamethasone to pomalido-
circumstances for patients with relapsed/refractory MM
mide/dexamethasone in patients (n570) with relapsed/
(category1).
refractory MM who had received more than two prior
therapies.46 Lenalidomide/Dexamethasone
The triple-drug combination significantly improved Lenalidomide combined with dexamethasone received
theORR($PR,64.7%vs38.9%;P5.0355).ThemedianPFS approvalfromtheFDAasatreatmentoptionforpatients
reported was 9.5 versus 4.4 months. No significant differ- withMMwhohadreceivedatleastonepriortreatment.
ences were seen in adverse event reports between the Thiswasbasedontheresultsof2studieswithatotalof
treatment arms; grade 3 and 4 anemia, neutropenia, and 692 patients randomized to receive dexamethasone
JNCCN.org | Volume21 Issue12 | December2023 1291

NCCNGUIDELINES® MultipleMyeloma, Version2.2024
eitherwithorwithoutlenalidomide.Theprimaryefficacy linesoftherapy,includingaPIandanIMiD.Indaratu-
endpointin bothstudies was time to progression (TTP). mumab-naïve patients, the ORR was 73%, with 11 VGPR
A preplanned interim analysis of both studies reported and 11 PR. The median PFS was 12.5 months. This regi-
thatthemedianTTPwassignificantlylongerinthelena- menhasbeenincludedunderthelistofregimensusefulin
lidomide arm compared with the control group.52,53 The certaincircumstancesforrelapsed/refractoryMM.
updated clinical data from the pivotal North American
phase III trial (MM-009) in 353 previously treated pa- Selinexor/Carfilzomib/Dexamethasone
tients withMM reported increased OSand mediantime Inastudyof32patientswhohadreceivedamedianof
todiseaseprogressioninpatientsreceivinglenalidomide 4priortherapieswereassignedtoreceiveonceweekly
plus dexamethasone compared with patients receiving selinexor, carfilzomib, and dexamethasone. The ORR was
dexamethasoneplusplacebo.53Similarresultswereseen 78%withamedianPFSof15months.Themostcommon
in the international trial MM-010.52 Patients in both of grade 3 or higher treatment-related adverse events were
these trials had been heavily treated before enrollment. thrombocytopenia(47%),nausea(6%),anemia(19%),and
Many had 3 or more prior lines of therapies with other fatigue(9%).56
agents and more than 50% of patients had undergone Another analysis of a subset of this patient popula-
HCT.52,53 Most adverse events and grade 3/4 adverse tion that had triple-class refractory MM also showed an
eventsweremorefrequentinpatientswithMMwhore- ORRof66.7%withamedianPFSof13.8monthsandme-
ceivedthecombinationoflenalidomide/dexamethasone dianOSof33months.57
compared with placebo and dexamethasone. Thrombo- Thisregimenhasnowbeenincludedunderthelistof
cytopenia (61.5%) and neutropenia (58.8%) were the regimens“usefulincertaincircumstances” forrelapsed/
most frequently reported adverse events observed. The refractoryMM.
NCCN MM Panel now considers this regimen as a cate-
gory 1 option that is useful in certain circumstances for Venetoclax/DexamethasoneWithorWithout
patientswithrelapsed/refractoryMM. DaratumumaborPIfort(11;14)Patients
AphaseIstudyofpatients(n566)withrelapsed/refractory
Carfilzomib/Cyclophosphamide/Thalidomide/ MM who received a median of 5 prior lines of therapy
Dexamethasone studied venetoclaxmonotherapyand reported anORR in
The results of the phase I/II trial showed that this 4-drug 21% ofpatients,withthe response rate higher inpatients
regimen is efficacious with an ORR of 91%, with 59% (n530)witht(11;14)comparedwiththosewithoutt(11:14)
experiencingVGPRorgreaterafter4cyclesinpatientswith (40% vs 6%).58 Similar higher response rates have been
MM.54ThePFSandOSat24months(median,17.5months)
foundinpatientswitht(11:14)inreal-worldexperienceas
were 76% and 96%, respectively.54 This regimen has now
well.59 An open-label phase I/II study examined veneto-
beenincludedunderthelistofregimens“usefulincertain
clax/dexamethasoneinheavilypretreatedt(11;14)patients.
circumstances”forrelapsed/refractoryMM.
In this phase II part of the study, patients had received a
medianof 5prior lines of therapy.At amedianfollow-up
Carfilzomib(Weekly)/Dexamethasone
of 9.2 months, the ORR was 48%, with a median TTP of
InthephaseIIIA.R.R.O.W.trial,patients(n5578)withre-
10.8months.60
lapsed and refractory MM previously treated with 2 or 3
Severalprospectivetrialshavereportedontheefficacy
treatments, including PI and IMiD were randomly as-
signed(1:1)toreceivecarfilzomibonceaweek(70mg/m2) and tolerability of venetoclax/dexamethasone–containing
combinationregimensinrelapsedt(11;14)MM.AphaseI
or twice a week (27 mg/m2). All patients received dexa-
study found that venetoclax/dexamethasone in combina-
methasone.ThemediaPFSwashigherintheonceweekly
tion with daratumumabwith or without bortezomib pro-
(11.2 months) compared with those who received twice
weeklycarfilzomib(7.6months;HR0.69,95%CI0.54-0.83; duced high rates of durable responses in patients with
P5.0029).Theoverallsafetywascomparablebetweenthe relapsedorrefractoryMMwitht(11;14)translocation.61
twogroups.55TheNCCNpanelhasincludedthiscombina- In patients with no prior treatment with carfilzomib,
tion on the list of regimens “useful in certain circum- venetoclax/dexamethasone plus carfilzomib was found to
stances”forrelapsed/refractoryMM. be safe and efficacious, especially in those with t(11;14)
translocations.62 This finding has been supported by case
Selinexor/daratumumab/dexamethasone studies.63
AphaseIb/IItrialassessedthesafetyandefficacyofadd- The NCCN Guidelines Panel included venetoclax/
ing daratumumab to selinexor dexamethasone. Patients dexamethasonewithorwithoutdaratumumaboraPIas
(n534) enrolled in the trial had received 3 or more prior optionsforpatientswitht(11:14)translocation.
1292 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume21 Issue12 | December2023

MultipleMyeloma,Version2.2024 NCCNGUIDELINES®
Pomalidomide/Dexamethasone TheFDAhasapprovedpomalidomideforpatientswith
Pomalidomide, like lenalidomide, is an analogue of tha- MMwhohavereceivedatleast2priortherapiesincluding
lidomide. It possesses potent immunomodulatory and lenalidomideandbortezomibandhavedemonstrateddis-
significantantimyelomaproperties.64
easeprogressiononorwithin60daysofcompletionofthe
A phase III, multicenter, randomized, open-label lasttherapy.TheFDA-recommendeddoseandscheduleof
study(MM-003)conductedinEuropecomparedtheeffi-
pomalidomide is 4 mg orally on days 1 to 21 of repeated
cacy and safety of pomalidomide and low-dose dexa- 28-daycycles,withcyclesrepeateduntildiseaseprogression
methasone (n5302) versus high-dose dexamethasone alongwiththerecommendationtomonitorpatientsforhe-
(n5153)inpatientswithrelapsedMMrefractorytoboth
matologictoxicities,especiallyneutropenia.
lenalidomideandbortezomib.65Afteramedianfollow-up Basedonthesedata,thepanelhasincludedpomali-
of10months,PFS,theprimaryendpointofthestudy,was domide plus dexamethasone as a therapeutic option in
significantly longer in patients who received pomalido- patientswhohavereceivedatleast2priortherapies,in-
mideandlow-dosedexamethasonecomparedwiththose cluding an IMiD and a PI, and have demonstrated dis-
whoreceivedhigh-dosedexamethasone(4vs1.9months; ease progression on or within 60 days of completion of
HR, 0.45; P,.0001).65 The median OS was also signifi- thelasttherapy(category1).
cantlylongerinthepatientswhoreceivedpomalidomide
and low-dose dexamethasone (12.7 vs 8.1 months; HR, Selinexor/Pomalidomide/Dexamethasone
0.74;P5.0285).65Themostcommonhematologicgrade3 Anabstractpresentedatthe2021ASCOAnnualMeeting
and 4 adverse effects found to be higher with the low- presented data from an ongoing phase I/II clinical trial
dosedexamethasonecomparedwiththehigh-dosedexa- that contains one arm evaluating the regimen of seli-
methasone were neutropenia and pneumonia.65 Other nexor/pomalidomide/dexamethasone (ClinicalTrials.gov
phase III studies of pomalidomide plus low-dose dexa- identifier: NCT02343042). Sixty-five patients were en-
methasoneincombinationwithotheragents(eg,bortez- rolledinitiallyinphaseIwithamedianof3priorlinesof
omib) are currently ongoing (ClinicalTrials.gov identifier: therapy. After determining a recommended phase II
NCT01734928). dose,itwasadministeredto20patients.Amongthesepa-
AEuropeanmulticenter,single-arm,open-label,phase tients, the ORR was 65% and the median PFS was not
IIIbtrialevaluatedthesafetyandefficacyofpomalidomide reachedinamedianfollowupof3.9months.69Basedon
andlow-dosedexamethasoneinalargepatientpopulation thesedata,theNCCNGuidelinesPanelhasincludedseli-
(n5604).66 ThemedianPFSreported was4.2months and nexor/pomalidomide/dexamethasone as a therapeutic
OS was 11.9 months. Whether the patients received prior optioninpatientswhohavereceivedatleast2priorther-
lenalidomide or bortezomib, the PFS, OS, and ORR re- apies,includinganIMiDandbortezomib,andhavedem-
portedweresimilar.66Theresultsofthistrialareconsistent onstrated disease progression on or within 60 days of
withthoseobservedinthepivotalMM-003trial.65 completionofthelasttherapy(category1).
Inaddition,several complementaryphase IIstud-
ies have been published evaluating the use of pomalido- Daratumumab
mide and dexamethasone in patients with MM relapsed/ Daratumumab is a human immunoglobulin G kappa
refractory to lenalidomide and/or bortezomib. A phase II monoclonal antibody that targets the CD38 surface pro-
studyinvestigated2differentdoseregimensofpomalido- tein on myeloma cells.19 In a phase I/II study, patients
mide and dexamethasone in 84 patients with advanced whohadreceivedmorethan3linesoftherapyincluding
MM. Pomalidomide (4 mg) was given orally on days 1 to an IMiD and a PI or were double refractory to PI and
21 or continuously over a 28-day cycle, and dexametha- IMiDwererandomizedto2differentdosesofdaratumu-
sone(40mg)wasgivenorallyonceweekly.67ORRwas35% mab (8 mg/kg vs 16 mg/kg). Findings from 106 patients
and34%forpatientsinthe21-dayand28-daygroups, whoreceived16mg/kgnotedanORRof29.2%in31pa-
respectively. Withamedianfollow-upof23months,me- tients (3 stringent CR [sCR], 10 VGPR, and 18 PR). The
diandurationofresponse,PFS,andOSwere7.3,4.6,and median duration of response was 7.4 months and me-
14.9 months across both groups, respectively. All patients dian TTP was 3.7 months. The estimated 1-year OS rate
experiencedsimilaradverseeventsinbothgroups.Thead- was65%.20Adverseeventsreportedwerefatigue(39.6%),
verseeventswereprimarilyduetomyelosuppression.67An- anemia (33.0%), nausea (29.2%), and thrombocytopenia
other phase II trial evaluated 2 doses of pomalidomide, (25.5%). Grade 1 and 2 infusion-related reactions were
2or4mg/daywithdexamethasone40mgweeklyinheavily seenin42.5%ofpatients,mainlyduringfirstinfusion.No
pretreated patients(n535).68 The ORR in the 2-mg cohort patients discontinued the study due to infusion-related
was 49% versus 43% in the 4-mg cohort. OS at 6 months reactions.20
was78%and67%inthe2-and4-mgcohort,respectively. Based on the noted phase II results and FDA ap-
Myelosuppressionwasthemostcommontoxicity.68 proval, the panel has added daratumumab as an option
JNCCN.org | Volume21 Issue12 | December2023 1293

NCCNGUIDELINES® MultipleMyeloma, Version2.2024
forthetreatmentofpatientswithMMwhohavereceived Teclistamab-cqyv
at least 3 prior lines of therapy including a PI and an Teclistamab-cqyv,similartoelranatamab-bcmm,isabis-
IMiDorwhoaredoublerefractorytoaPIandIMiD. pecific T-cell engager that binds to CD3 on T cells and
BCMA on myeloma cells. A phase I/II study examined
DCEPandVTD-PACEforAggressiveMM the T cell–redirecting bispecific antibody teclistamab-
Patients with an aggressive relapse may need multidrug cqyv in 165 patients who had triple class refractory dis-
combinations such as
DCEP,70–72
TD-PACE (thalidomide, ease, with a median of 5 prior lines of therapy.80 After a
dexamethasone, cisplatin, doxorubicin, high-dose cyclo- medianfollowupof14.1months,theORRwas63%,and
phosphamide,andetoposide),73,74andVTD-PACE(bortez- 39.4% of patients demonstrateda CR or better.The me-
omib,thalidomide,dexamethasone,cisplatin,doxorubicin, dianPFSwas11.3months,withamedianresponsedura-
cyclophosphamide,andetoposide)75–77foreffectivedisease
tion of 18.4 months. Common adverse events included
control. cytokine release syndrome in 72.1% of patients (0.6%
grade3) and grade3 or 4 hematologic toxicity including
neutropenia(64.2%),anemia(37%),andthrombocytope-
PreferredRegimensforRelapseAfter
nia (21.2%). Infections were also common, with grade 3
4PriorTherapies
Currentlythereare3bispecificantibodies(elranatamab- or4infectionoccurringin44.8%ofpatients.
bcmm, talquetamab-tgvs, and teclistamab-cqyv) and 2
CART-CellTherapies
CAR T-cell therapies (idecabtagene vicleucel and cilta-
Idecabtagene vicleucel
cabtageneautoleucel)approvedbytheFDAandincluded
Idecabtagene vicleucel is a BCMA-directed CAR T-cell
as preferred options by the NCCN Guidelines Panel for
therapy. In a phase II study (n5128) patients with re-
relapsed/refractoryMMafteratleast4priortherapiesin-
lapsed and refractory MM who had received at least 3
cludingananti-CD38monoclonalantibody,aPI,andan
prior regimens (including a PI, an IMiD, and an anti-
IMiD.
CD38antibody)receivedidecabtagenevicleucel.Patients
BispecificAntibodies had received a median of 6 previous regimens for MM
and94%hadreceivedHCT.Inthispopulationofheavily
Elranatamab-bcmm
pretreatedpatients,afteramedian13monthsfollowup,
Elranatamab-bcmm is a bispecific T-cell engager that
73%ofpatientsdemonstratedresponse,with33%having
binds CD3 on T cells and to B-cell maturation antigen
aCRorbetter.Themediantimetoresponsewas1month
(BCMA)onmyelomacells.InthephaseII,MagnetisMM-3
and mediantime toaCRor better was 2.8months.High
trial,patientswithrelapsed/refractoryMMreceivedsubcu- response rates (.50%) were found in several examined
taneous elranatamab once weekly.78 The primary popula-
subgroupsincludingolderpatients,patientswithhigh-risk
tioninwhomtheefficacywasseenwerepatients(n5123)
cytogenetic abnormalities, pentarefractory disease, and
without prior BCMA-directed therapy. The findings indi- high tumor burden. Adverse events at grade 3 or 4 were
catedanORRof61.0%(75/123)and35.0%greaterthanor commonandincludedneutropenia(91%),anemia(70%),
equaltoCR.Fiftyrespondersswitchedtobiweeklydosing, and thrombocytopenia(63%).Twenty-eightpatientswere
and 40 of those(80.0%) improved or maintained their re- retreatedwithidecabtagenevicleucelafterdiseaseprogres-
sponse for $6months. Common adverse events reported sionand21%showedasecondresponse.Grade3or4ad-
wereinfections,cytokinereleasesyndrome,anemia,and verse events were common and were reported in 99% of
neutropenia. With biweekly dosing, grade 3–4 adverse patients.Themostcommonadverseeventswererelatedto
eventsdecreasedfrom58.6%to46.6%.78 hematologic toxicity such as neutropenia (89%), anemia
(60%),andthrombocytopenia(52%).Infections(69%)and
Talquetamab-tgvs cytokinereleasesyndrome(84%)werealsocommontreat-
TalquetamabisaTcell–redirectingbispecificantibodytar-
ment-related adverse events, although the incidence of
getingbothGPRC5DandCD3onTcells.Inthesingle-arm, grade 3 or higher cytokine release syndrome was lower
open-label,multicenter trial,MMY1001(MonumenTAL-1) (5%).81TheNCCNGuidelinesPanelhasincludedidecabta-
patients (n5187) who had previously received at least genevicleucelasanoptionforpatientswhohavereceived
4 prior systemic therapies received talquetamab-tgvs atleast4priortherapies,includingananti-CD38monoclo-
subcutaneouslyweeklyortalquetamab-tgvsbiweeklyuntil nalantibody,aPI,andanIMiD.
disease progression or unacceptable toxicity.79 The most
common adverse reactions reported with weekly and bi- Ciltacabtagene Autoleucel
weekly dosing were cytokine release syndrome (in 77% CiltacabtageneautoleucelisanotherBCMA-directedCAR
and 80% of the patients, respectively), skin-related events T-cell therapy. The CARTITUDE-1 trial (n597) was an
(in67%and70%),anddysgeusia(in63%and57%).79 open label phase Ib/II study with the goal of assessing
1294 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume21 Issue12 | December2023

MultipleMyeloma,Version2.2024 NCCNGUIDELINES®
thesafetyandefficacyofciltacabtageneautoleucelinpa- 11.6 months with a median OS of 30.4 months. The most
tientswithrelapsedorrefractoryMMwhohadreceived3 commonadverseeventsofgrade3orhigherincludedlym-
ormorepreviouslinesoftherapy(includinganIMiD,PI, phopenia(29%),neutropenia(25%),andthrombocytopenia
andanti-CD38antibody).82Themedianamountofprior (22%).88TheNCCNGuidelinesPanelhasincludedcarfilzo-
therapieswas6.Afteramedian12.4monthsoffollowup, mib in combination with bendamustine and dexametha-
theORRwas97%,with67%ofpatientsachievingsCR.The soneasatreatmentoptionforrelapsed/refractoryMM.
PFSratewas77%withan89%OSrate.Adverseeventsin-
Bendamustine/Lenalidomide/Dexamethasone
cludedneutropeniain95%ofpatientsandanemiain68%.
A multicenter phase I/II trial investigated the combina-
Othercommonadverseeventsincludedthrombocytopenia
tionofbendamustine,lenalidomide,anddexamethasone
(60%),leukopenia(61%),andlymphopenia(50%).Cytokine
astreatmentforpatients(n529)withrelapsed/refractory
release syndrome also occurred in 95% of patients. There
MM.89PRwasseenin52%(n513)ofpatients,withVGPR
were6deathsduetotreatment-relatedadverseevents.82A
in24%(n56)ofpatients.ThemedianPFSinthetrialwas
follow-up analysis at 18 months showed that responses
6.1months(95%CI,3.7–9.4months),andthe1-yearPFS
weredurable;18-monthPFSandOSrateswere66.0%and
rate was 20% (95% CI, 6%–41%).89 The panel has in-
80.9%respectively,withnonewobservedsafetysignals.83
cludedlenalidomideincombinationwithbendamustine
and dexamethasone as a treatment option for relapsed/
OtherRecommendedRegimensforRelapseAfter
refractoryMM.
3PriorTherapies
Bendamustine High-DoseorFractionatedCyclophosphamide
In a trial by Knop et al,84 31 patients who had experi- Studieshavereportedthathigh-dosecyclophosphamide
enced relapse after autologous transplantation were en- or hyperfractionated cyclophosphamide is efficacious
rolled to receive increasing doses of bendamustine. The particularly in patients needing immediate disease con-
ORRwas55%,withamedianPFSof26weeksforallpa- trol who have received multiple prior treatments.90,91
tients and 36 weeks for patients who received higher ThereforetheNCCNGuidelinesPanelhasincludedhigh
dosesofbendamustine(90–100mg/m2).Thetoxicitywas doseor fractionated cyclophosphamide as an option for
mildandmainlyhematologic.Aretrospectiveanalysisof relapsed/refractoryMM.
39 patients has reported that bendamustine is effective
Selinexor/Dexamethasone
andtolerableinpatientswithadvancedprogressiveMM,
Selinexor in combination with dexamethasone was
withanORRof36%.85
studied in a phase IIb trial (STORM) in patients with
The ECOG studied treatment with high-dose cyclo-
relapsed/refractoryMM.92Thepatientsinthetrialhad
phosphamideinpatientswithpoor-riskfeatureswhohad
multiple prior therapies and were refractory to IMIDs
disease that was refractory to prior chemotherapy.86 The
(lenalidomide and pomalidomide), PIs (bortezomib and
ORRreportedwas43%(29%responserateinpatientsre-
carfilzomib),andtheCD38antibodydaratumumab.Ato-
fractorytopriortherapywithcyclophosphamide).86Bend-
tal of 122 patients were included in the intent-to-treat
amustine is currently a treatment option for relapsed/
population.PRorbetterwasobservedin26%ofpatients
refractoryMM.
(95% CI, 19%–35% with sCR in 2%, VGPR in 5%, and PR
Bendamustine/Bortezomib/Dexamethasone in20%ofpatients.
A phase II study evaluated bendamustine/bortezomib/ The most common adverse events reported during
dexamethasone administered over six 28-day cycles and treatmentwerethrombocytopeniain73%ofthepatients,
then every 56 days for 6 more cycles in patients (n575; fatiguein73%,nauseain72%,andanemiain67%.
medianage68years)withrelapsed/refractoryMMtreated Based on these results, the NCCN MM Panel has in-
withmultiplepriortherapiesandnot refractorytobortez- cludedselinexor/dexamethasoneunderotherrecommended
omib.ThePRratewas71.5%(16%CR,18.5%VGPR,37% optionsforpatientswithrelapsed/refractoryMMwhohave
partial remission). At 12-month follow-up, median TTP received at least 4 prior therapies and whose disease is re-
was16.5months,and1-yearOSwas78%.87 fractorytoatleast2PI,atleast2immunomodulatoryagents,
andananti-CD38monoclonalantibody.56
Bendamustine/Carfilzomib/Dexamethasone
A multicenter trial evaluated combination therapy with
RegimensUsefulinCertainCircumstancesfor
bendamustine/carfilzomib/anddexamethasonein63pa-
RelapseAfter4PriorTherapies
tients with relapsed/refractory MM (with $2 lines of
prior therapy). Fifty-two percent of patients experienced BelantamabMafodotin-blmf
aPRorbetterand32%experiencedaVGPRorbetter.Af- Belantamabmafodotin-blmfisaBCMAantibody,conju-
teramedianfollowupof22months,themedianPFSwas gated to a microtubule disrupting agent—monomethyl
JNCCN.org | Volume21 Issue12 | December2023 1295

NCCNGUIDELINES® MultipleMyeloma, Version2.2024
auristatin—viaastable,proteaseresistantlinker.Itisthe withMMinitiatingchemotherapyregardlessofbonedis-
firstinitsclass.Intheopen-labelphaseIItrial(DREAMM- ease.Thepatientswererandomizedtoreceivezoledronic
2),belantamabmafodotinwasevaluatedinpatientswhose acid (n5981) or clodronic acid (n5979). Zoledronic acid
MM was refractory to multiple agents. Responses were was reported to reduce mortality and significantly im-
seen in approximately one-third of patients.93 The most prove PFS.98 Patients on clodronate and zoledronic acid
commongrade3/4adverseeventsinthesafetypopulation had similar occurrence of acute renal failure and treat-
werekeratopathy,thrombocytopenia,andanemia.93 ment-relatedseriousadverseevents.Zoledronicacidwas
In November 2022, it was announced that belanta- associated with higher rates of ONJ than was clodronic
mab mafodotin-blmf is being withdrawn because it did acid.99 An extended follow-up (median, 5.9 years) of the
notmeettheprimaryendpointofhavingasuperiorPFS MedicalResearchCouncilMyelomaIXshowedsignificant
compared with pomalidomide/dexamethasone in the improvement in OS (52 vs 46 months; HR, 0.86; P5.01)
DREAMM-3 trial (HR, 1.03; 95% CI, 0.72–1.47). The PFS compared with clodronic acid.100 The long-term rates of
withbelantamabmafodotin-blmfwas11.2monthscom- ONJwerealsoobservedtobehigherwithzoledronicacid
paredwith7monthsforpomalidomideplusdexametha- comparedwithclodronate(3.7%vs0.5%;P5.0001).100
sone;however,thiswasnotstatisticallysignificant.Since A recent meta-analysis of 20 randomized controlled
thattime,patientsalreadyreceivingbelantamabmafodo- trialscomparingbisphosphonateswitheitherplaceboor
tin-blmf and those enrolled on the FDA Risk Evaluation a different bisphosphonate as a comparator concluded
andMitigationStrategyprogramhavebeenabletocon- thataddingbisphosphonatestothetreatmentofMMre-
tinue to receive the drug through a compassionate use ducesvertebralfracturesandprobablyreducespain.101It
program. Other trials with belantamab mafodotin-blmf did not find a particular bisphosphonate to be superior
are ongoing. The NCCN Guidelines Panel has included to another.101 In a multicenter trial (CALGB 70604), pa-
thisasanoptionusefulincertaincircumstanceforthose tients with MM or bone metastases from a solid malig-
after 4 prior therapies (including a PI, an IMiD, and an nancy were randomly assigned to zoledronic acid either
anti-CD38monoclonalantibody). monthly or every 3 months for 2 years.102 The rates of
skeletal-relatedeventsweresimilarinbotharms.Among
Supportive Care for MM the278patientswithMM,ratesofskeletal-relatedevents
Importantadvanceshavebeenmadeinadjunctivetreat- were26%inthosereceivingmonthlyversus21%inthose
ment/supportivecareofpatientswithMM.Thisinvolves receivingtreatmentevery3months.102
carefulpatienteducationabouttheprobablesideeffects Alarge,placebo-controlled,randomizedtrialcompared
ofeachdrug,thedrugcombinationsbeingused,andthe denosumabwithzoledronicacidinpatients(n51,718)
supportive care measures required. Supportive care can withnewlydiagnosedMMwithbonelesions.Timetofirst
be categorized into those measures required for all pa- skeletal-relatedeventandOSweresimilarinbotharms.The
tientsandthosethataddressspecificdrugs. denosumabarmhadlowerratesofrenaltoxicityandhigher
Bony manifestations in the form of diffuse osteope- ratesofhypocalcemia.ONJwasslightlyhigherinthedeno-
nia and/or osteolytic lesions develop in 85% of patients sumabarm(3%vs2%)butnotstatisticallysignificant.103
with MM. Related complications are the major cause of TheNCCNGuidelinesforMMrecommendbisphosph-
limitations in quality of life and performance status in onates(category1)ordenosumabforallpatientsreceiving
patients with MM. A large, double-blind, randomized therapy for symptomatic MM regardless of documented
trialhasshownthatmonthlyuseofintravenouspamidr- bone disease. Denosumab is preferred by the NCCN MM
onate (a bisphosphonate) can decrease pain and bone- Panel in patients with renal disease. The panel recom-
relatedcomplications,improveperformancestatus,and, mends a baseline dental examination and monitoring for
importantly, preserve quality of life in patients with ONJ in all patients receiving a bone-modifying agent and
Durie-SalmonstageIIIMMandatleast1lyticlesion.94,95 monitoring for renal dysfunction with use of bisphospho-
Zoledronic acid has equivalent benefits.96 Results from natetherapy.Withrespecttodurationoftherapy,thepanel
the study conducted by Zervas et al97 show a 9.5-fold also recommends continuing bone-targeting treatment
greater risk for the development of osteonecrosis of the (bisphosphonatesordenosumab)forupto2years;con-
jaw(ONJ)withzoledronicacidcomparedwithpamidro- tinuing beyond 2 years should be based on clinical
nate. Patients who are on bisphosphonates should have judgement. The frequency of dosing (monthly vs every
their renal function monitored. They should undergo a 3months)woulddependontheindividualpatientcrite-
dentalexaminationbeforestartingbisphosphonatether- riaandresponsetotherapy.
apyandshouldbemonitoredforONJ. Excessboneresorptionfrombonediseasecanleadto
TheMedicalResearchCouncilMyelomaIXstudyex- excessive release of calcium into the blood, contributing
aminedeffectsofzoledronicacidversusclodronate(abi- tohypercalcemia.Symptomsincludepolyuriaandgastro-
sphosphonate not currently FDA approved) in patients intestinaldisturbances,withprogressivedehydrationand
1296 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume21 Issue12 | December2023

MultipleMyeloma,Version2.2024 NCCNGUIDELINES®
decreases in glomerular filtration rate. Hypercalcemia their use of plasmapheresis for adjunctive treatment of
should be treated with hydration, bisphosphonates, renaldysfunction.
denosumab,103 steroids, and/or calcitonin. Among the Erythropoietin therapy may be considered for pa-
bisphosphonates (zoledronic acid, pamidronate, and tients with anemia, especially those with renal failure.
ibandronate), the NCCN MM Panel members prefer Measuringendogenouserythropoietinlevelsmayalsobe
zoledronicacidfortreatmentofhypercalcemia.96,104,105 helpfulintreatmentplanning110,111(seeNCCNGuidelines
The panel has provided general principles of pallia- for Prevention and Treatment of Cancer-Related Infec-
tiveradiationtherapyforpatientswithMM.Carefulplan- tions, available at NCCN.org). Daratumumab can inter-
ning of the radiation field and radiation technique is fere with cross-matching and red blood cell antibody
important to minimize toxicity to the spinal cord, brain, screening. The NCCN MM Panel recommends perform-
bone marrow, and adjacent organs at risk because pa- ingtypeandscreenbeforereceivingdaratumumabtoin-
tientswithMMmaybetreatedmultipletimesduringthe formfuturematching.
diseasecourse.Thepanelhasnotedthatinitiationofsys- Thehighestriskforvenousthromboembolism(VTE)
temic therapy should not be delayed for radiation ther- isinthefirst6monthsafteranewdiagnosisofMM.The
apy and can often be given concurrently and that NCCNMMPanelhasoutlinedmanagementofVTE,risk
patientsshouldbecarefullymonitoredfortoxicities.106,107 stratification, and VTE prophylaxis in a separate section
Low-dose radiation therapy (8 Gy 3 1 fraction) or 20 to intheNCCNGuidelinesforMM(availableatNCCN.org),
30 Gy in 5 to 10 total fractions can be used as palliative and VTE prophylaxis is administered to all patients, as-
treatment for uncontrolled pain, for impending patho- sumingtherearenocontraindicationstoanticoagulation
logicfracture,orforimpendingcordcompression.Moder- agentsorantiplatelets(seeNCCNGuidelinesforCancer-
atelyfractionatedcoursesof20to25Gyin8to10fractions Associated Venous Thromboembolic Disease, available
aregenerallypreferredoverhigherdoses(30Gy)absentex- atNCCN.org).
tenuating circumstances (eg, severe symptomatic cord TopreventinfectionsinpatientswithMM,thepanel
compression)tolimitunnecessarytoxicityandreducerisk recommends referring to the NCCN Guidelines for Pre-
of future treatment of adjacent or overlapping organs at vention and Treatment of Cancer-Related Infections
risk (eg, spinal cord).108 For radiation therapy dose con- (available at NCCN.org) and the CDC recommendations
straint suggestions regarding bone marrow and other or- forUseofCOVID-19VaccinesintheUnitedStates.Inthe
gansatrisk,seeNCCNGuidelinesforHodgkinLymphoma mostrecentupdate,theNCCNMMGuidelinesPanelhas
(availableatNCCN.org). outlinedrecommendationsforprophylaxisandmanage-
Plasmapheresisshouldbeusedasadjunctivetherapy mentofinfectionsinpatientsundergoingtreatmentwith
for symptomatic hyperviscosity.109 Institutions differ in CART-cellandbispecificantibody.
References
1. SEER.Cancerstatfacts:myeloma.AccessedOctober25,2024. 9. DimopoulosMA,TerposE,BoccadoroM,etal.Daratumumabplus
Availableat:https://seer.cancer.gov/statfacts/html/mulmy.html pomalidomideanddexamethasoneversuspomalidomideanddexa-
2. SiegelRL,MillerKD,WagleNS,etal.Cancerstatistics,2023.CA methasonealoneinpreviouslytreatedmultiplemyeloma(APOLLO):
CancerJClin2023;73:17–48. anopen-label,randomised,phase3trial.LancetOncol2021;22:
801–812.
3. ChariA,Martinez-LopezJ,MateosMV,etal.Daratumumabpluscar-
filzomibanddexamethasoneinpatientswithrelapsedorrefractory 10. SiegelDS,SchillerGJ,SamarasC,etal.Pomalidomide,dexametha-
multiplemyeloma.Blood2019;134:421–431. sone,anddaratumumabinrelapsedrefractorymultiplemyelomaafter
lenalidomidetreatment.Leukemia2020;34:3286–3297.
4. DimopoulosM,QuachH,MateosMV,etal.Carfilzomib,dexametha-
sone,anddaratumumabversuscarfilzomibanddexamethasoneforpa- 11. AttalM,RichardsonPG,RajkumarSV,etal.Isatuximabpluspomalido-
mideandlow-dosedexamethasoneversuspomalidomideandlow-
tientswithrelapsedorrefractorymultiplemyeloma(CANDOR):results
dosedexamethasoneinpatientswithrelapsedandrefractorymultiple
fromarandomised,multicentre,open-label,phase3study.Lancet
2020;396:186–197. m stuy del yo .m Laa n( cIC etA 2R 0IA 1- 9M ;3M 94): :2a 0r 9a 6n –d 2o 1m 07is .ed,multicentre,open-label,phase3
5. UsmaniSZ,QuachH,MateosMV,etal.Carfilzomib,dexamethasone,
12. DimopoulosMA,LeleuX,MoreauP,etal.Isatuximabpluspomalido-
anddaratumumabversuscarfilzomibanddexamethasoneforpatients
mideanddexamethasoneinrelapsed/refractorymultiplemyelomapa-
withrelapsedorrefractorymultiplemyeloma(CANDOR):updatedout- tientswithrenalimpairment:ICARIA-MMsubgroupanalysis.Leukemia
comesfromarandomised,multicentre,open-label,phase3study.Lan- 2021;35:562–572.
cetOncol2022;23:65–76.
13. VoorheesPM,SumanVJ,TuchmanSA,etal.AphaseI/IIstudyofixazo-
6. MoreauP,DimopoulosMA,MikhaelJ,etal.Isatuximab,carfilzomib,and mib,pomalidomide,anddexamethasoneforlenalidomideandprotea-
dexamethasoneinrelapsedmultiplemyeloma(IKEMA):amulticentre, someinhibitorrefractorymultiplemyeloma(AllianceA061202).AmJ
open-label,randomisedphase3trial.Lancet2021;397:2361–2371. Hematol2021;96:1595–1603.
7. SonneveldP,ZweegmanS,CavoM,etal.Carfilzomib,pomalidomide, 14. KrishnanAY,KapoorP,PalmerJ,etal.AphaseI/IIstudyofixazomib
anddexamethasoneassecond-linetherapyforlenalidomide-refractory (Ix)pomalidomide(POM)dexamethasone(DEX)inrelapsedrefractory
multiplemyeloma.HemaSphere2022;6:e786. (R/R)multiplemyeloma:initialresults.JClinOncol2016;34
8. ChariA,SuvannasankhaA,FayJW,etal.Daratumumabpluspomali- (Suppl):Abstract8008.
domideanddexamethasoneinrelapsedand/orrefractorymultiple 15. DimopoulosMA,OriolA,NahiH,etal.Daratumumab,lenalidomide,and
myeloma.Blood2017;130:974–981. dexamethasoneformultiplemyeloma.NEnglJMed2016;375:1319–1331.
JNCCN.org | Volume21 Issue12 | December2023 1297

NCCNGUIDELINES® MultipleMyeloma, Version2.2024
16. BahlisNJ,DimopoulosMA,WhiteDJ,etal.Daratumumabpluslenali- 37. RichardsonPG,XieW,JagannathS,etal.Aphase2trialoflenalido-
domideanddexamethasoneinrelapsed/refractorymultiplemyeloma: mide,bortezomib,anddexamethasoneinpatientswithrelapsedand
extendedfollow-upofPOLLUX,arandomized,open-label,phase3 relapsed/refractorymyeloma.Blood2014;123:1461–1469.
study.Leukemia2020;34:1875–1884. 38. YongKL,HinsleyS,AunerHW,etal.Carfilzomiborbortezomibincom-
17. StewartAK,RajkumarSV,DimopoulosMA,etal.Carfilzomib,lenalido- binationwithcyclophosphamideanddexamethasonefollowedbycarfil-
mide,anddexamethasoneforrelapsedmultiplemyeloma.NEnglJ zomibmaintenanceforpatientswithmultiplemyelomaafteroneprior
Med2015;372:142–152. therapy:resultsfromamulticenter,phaseII,randomized,controlledtrial
18. PalumboA,Chanan-KhanA,WeiselK,etal.Daratumumab,bortezo- (MUKfive).Haematologica2021;106:2694–2706.
mib,anddexamethasoneformultiplemyeloma.NEnglJMed2016; 39. PuertasB,Gonza(cid:2)lez-CalleV,SuredaA,etal.RandomizedphaseIIstudy
375:754–766. ofweeklycarfilzomib70mg/m2anddexamethasonewithorwithoutcy-
19. LokhorstHM,PlesnerT,LaubachJP,etal.TargetingCD38withdaratu- clophosphamideinrelapsedand/orrefractorymultiplemyelomapa-
mumabmonotherapyinmultiplemyeloma.NEnglJMed2015;373: tients.Haematologica2023;108:2753–2763.
1207–1219.
40. YimerH,MelearJ,FaberE,etal.Daratumumab,bortezomib,
20. LonialS,WeissBM,UsmaniSZ,etal.Daratumumabmonotherapyin cyclophosphamideanddexamethasoneinnewlydiagnosedand
patientswithtreatment-refractorymultiplemyeloma(SIRIUS):anopen- relapsedmultiplemyeloma:LYRAstudy.BrJHaematol2019;185:
label,randomised,phase2trial.Lancet2016;387:1551–1560. 492–502.
21. MateosMV,SonneveldP,HungriaV,etal.Daratumumab,bortezomib, 41. JakubowiakA,OffidaniM,Pe(cid:2)gourieB,etal.Randomizedphase2study:
anddexamethasoneversusbortezomibanddexamethasoneinpatients elotuzumabplusbortezomib/dexamethasonevsbortezomib/dexameth-
withpreviouslytreatedmultiplemyeloma:three-yearfollow-upof asoneforrelapsed/refractoryMM.Blood2016;127:2833–2840.
CASTOR.ClinLymphomaMyelomaLeuk2020;20:509–518.
42. KumarSK,BuadiFK,LaPlantB,etal.Phase1/2trialofixazomib,cyclo-
22. RichardsonPG,OriolA,BeksacM,etal.Pomalidomide,bortezomib, phosphamideanddexamethasoneinpatientswithpreviouslyuntreated
anddexamethasoneforpatientswithrelapsedorrefractorymultiple symptomaticmultiplemyeloma.BloodCancerJ2018;8:70.
myelomapreviouslytreatedwithlenalidomide(OPTIMISMM):arando- 43. DimopoulosMA,GrosickiS,JRedrzejczakWW,etal.All-oralixazomib,
mised,open-label,phase3trial.LancetOncol2019;20:781–794.
cyclophosphamide,anddexamethasonefortransplant-ineligiblepa-
23. DimopoulosM,WeiselK,MoreauP,etal.Pomalidomide,bortezomib, tientswithnewlydiagnosedmultiplemyeloma.EurJCancer2019;106:
anddexamethasoneformultiplemyelomapreviouslytreatedwithlenali- 89–98.
domide(OPTIMISMM):outcomesbypriortreatmentatfirstrelapse.
44. KumarSK,GrzaskoN,DelimpasiS,etal.Phase2studyofall-oralixazo-
Leukemia2021;35:1722–1731.
mib,cyclophosphamideandlow-dosedexamethasoneforrelapsed/re-
24. GrosickiS,SimonovaM,SpickaI,etal.Once-per-weekselinexor,bor- fractorymultiplemyeloma.BrJHaematol2019;184:536–546.
tezomib,anddexamethasoneversustwice-per-weekbortezomiband
45. MorganGJ,ScheySA,WuP,etal.Lenalidomide(Revlimid),incombi-
dexamethasoneinpatientswithmultiplemyeloma(BOSTON):arando-
nationwithcyclophosphamideanddexamethasone(RCD),isaneffec-
mised,open-label,phase3trial.Lancet2020;396:1563–1573.
tiveandtoleratedregimenformyelomapatients.BrJHaematol2007;
25. DimopoulosMA,DytfeldD,GrosickiS,etal.Elotuzumabpluspomali- 137:268–269.
domideanddexamethasoneformultiplemyeloma.NEnglJMed
2018;379:1811–1822. 46. BazRC,MartinTG3rd,LinHY,etal.Randomizedmulticenterphase2
studyofpomalidomide,cyclophosphamide,anddexamethasoneinre-
26. DimopoulosMA,DytfeldD,GrosickiS,etal.Elotuzumabpluspomali- lapsedrefractorymyeloma.Blood2016;127:2561–2568.
domideanddexamethasoneforrelapsed/refractorymultiplemyeloma:
finaloverallsurvivalanalysisfromtherandomizedphaseIIELOQUENT-3 47. GarderetL,PolgeE,GueyemS,etal.Pomalidomide,cyclophospha-
trial.JClinOncol2023;41:568–578. mideanddexamethasoneforrelapsed/refractorymultiplemyeloma:a
retrospectivesinglecenterexperience.Blood2015;126:1858.
27. DimopoulosMA,MoreauP,PalumboA,etal.Carfilzomibanddexa-
48. OrlowskiRZ,NaglerA,SonneveldP,etal.RandomizedphaseIIIstudy
methasoneversusbortezomibanddexamethasoneforpatientswith
ofpegylatedliposomaldoxorubicinplusbortezomibcomparedwith
relapsedorrefractorymultiplemyeloma(ENDEAVOR):arando-
bortezomibaloneinrelapsedorrefractorymultiplemyeloma:com-
mised,phase3,open-label,multicentrestudy.LancetOncol2016;
17:27–38. binationtherapyimprovestimetoprogression.JClinOncol2007;
25:3892–3901.
28. DimopoulosMA,GoldschmidtH,NiesvizkyR,etal.Carfilzomiborbor-
49. MikhaelJR,BelchAR,PrinceHM,etal.Highresponseratetobortezo-
tezomibinrelapsedorrefractorymultiplemyeloma(ENDEAVOR):anin-
mibwithorwithoutdexamethasoneinpatientswithrelapsedorrefrac-
terimoverallsurvivalanalysisofanopen-label,randomised,phase3
trial.LancetOncol2017;18:1327–1337. torymultiplemyeloma:resultsofaglobalphase3bexpandedaccess
program.BrJHaematol2009;144:169–175.
29. LonialS,DimopoulosMA,PalumboA,etal.Elotuzumabtherapyforre-
lapsedorrefractorymultiplemyeloma.NEnglJMed2015;373:621–631. 50. JagannathS,BarlogieB,BerensonJ,etal.Aphase2studyoftwo
dosesofbortezomibinrelapsedorrefractorymyeloma.BrJHaematol
30. DimopoulosMA,LonialS,WhiteD,etal.Elotuzumabpluslenalidomide/ 2004;127:165–172.
dexamethasoneforrelapsedorrefractorymultiplemyeloma:ELOQUENT-2
follow-upandpost-hocanalysesonprogression-freesurvivalandtumour 51. JagannathS,RichardsonPG,BarlogieB,etal.Bortezomibincombina-
growth.BrJHaematol2017;178:896–905. tionwithdexamethasoneforthetreatmentofpatientswithrelapsed
and/orrefractorymultiplemyelomawithlessthanoptimalresponseto
31. aD nim do dp eo xu amlos etM haA s, oL no en ii nal RS R, MW Mh :ite finD a, loet vea rl a. lE ll so ut ru vz ivu am la reb s, ule ltn sa frli od mom thid ee, bortezomibalone.Haematologica2006;91:929–934.
phase3randomizedELOQUENT-2study.BloodCancerJ2020;10:91. 52. DimopoulosMA,SpencerA,AttalM,etal.Lenalidomideplusdexa-
methasoneforrelapsedorrefractorymultiplemyeloma.NEnglJMed
32. KumarSK,BerdejaJG,NiesvizkyR,etal.Safetyandtolerabilityofixazo- 2007;357:2123–2132.
mib,anoralproteasomeinhibitor,incombinationwithlenalidomideand
dexamethasoneinpatientswithpreviouslyuntreatedmultiplemyeloma: 53. WeberDM,ChenC,NiesvizkyR,etal.Lenalidomideplusdexametha-
anopen-labelphase1/2study.LancetOncol2014;15:1503–1512. soneforrelapsedmultiplemyelomainNorthAmerica.NEnglJMed
2007;357:2133–2142.
33. MoreauP,MassziT,GrzaskoN,etal.Oralixazomib,lenalidomide,and
dexamethasoneformultiplemyeloma.NEnglJMed2016;374:1621–1634. 54. MikhaelJR,ReederCB,LibbyEN,etal.PhaseIb/IItrialofCYKLONE
(cyclophosphamide,carfilzomib,thalidomideanddexamethasone)for
34. DaviesFE,WuP,JennerM,etal.Thecombinationofcyclophospha-
newlydiagnosedmyeloma.BrJHaematol2015;169:219–227.
mide,velcadeanddexamethasoneinduceshighresponserateswith
comparabletoxicitytovelcadealoneandvelcadeplusdexamethasone. 55. MoreauP,MateosMV,BerensonJR,etal.Onceweeklyversustwice
Haematologica2007;92:1149–1150. weeklycarfilzomibdosinginpatientswithrelapsedandrefractorymulti-
35. KropffM,BispingG,SchuckE,etal.Bortezomibincombinationwithin- plemyeloma(A.R.R.O.W.):interimanalysisresultsofarandomised,
termediate-dosedexamethasoneandcontinuouslow-doseoralcyclo-
phase3study.LancetOncol2018;19:953–964.
phosphamideforrelapsedmultiplemyeloma.BrJHaematol2007;138: 56. GasparettoC,SchillerGJ,TuchmanSA,etal.Onceweeklyselinexor,
330–337. carfilzomibanddexamethasoneincarfilzomibnon-refractorymultiple
36. RichardsonPG,WellerE,JagannathS,etal.Multicenter,phaseI,
myelomapatients.BrJCancer2022;126:718–725.
dose-escalationtrialoflenalidomideplusbortezomibforrelapsed 57. SchillerGJ,TuchmanSA,CallanderN,etal.Onceweeklyselinexor,car-
andrelapsed/refractorymultiplemyeloma.JClinOncol2009;27: filzomibanddexamethasone(XKd)intripleclassrefractorymultiplemy-
5713–5719. eloma.Blood2022;140(Suppl1):10050–10053.
1298 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume21 Issue12 | December2023

MultipleMyeloma,Version2.2024 NCCNGUIDELINES®
58. KumarS,KaufmanJL,GasparettoC,etal.Efficacyofvenetoclaxastar- 81. MunshiNC,AndersonLDJr,ShahN,etal.Idecabtagenevicleucelin
getedtherapyforrelapsed/refractoryt(11;14)multiplemyeloma.Blood relapsedandrefractorymultiplemyeloma.NEnglJMed2021;384:
2017;130:2401–2409. 705–716.
59. BasaliD,ChakrabortyR,RybickiL,etal.Real-worlddataonsafetyand 82. BerdejaJG,MadduriD,UsmaniSZ,etal.Ciltacabtageneautoleucel,a
efficacyofvenetoclax-basedregimensinrelapsed/refractoryt(11;14) B-cellmaturationantigen-directedchimericantigenreceptorT-celltherapy
multiplemyeloma.BrJHaematol2020;189:1136–1140. inpatientswithrelapsedorrefractorymultiplemyeloma(CARTITUDE-1):a
60. KaufmanJL,GasparettoC,SchjesvoldFH,etal.TargetingBCL-2with
phase1b/2open-labelstudy.Lancet2021;398:314–324.
venetoclaxanddexamethasoneinpatientswithrelapsed/refractory 83. MartinT,UsmaniSZ,BerdejaJG,etal.UpdatedresultsfromCARTITUDE-1:
t(11;14)multiplemyeloma.AmJHematol2021;96:418–427. phase1b/2studyofciltacabtageneautoleucel,aB-cellmaturationantigen-
61. BahlisNJ,BazR,HarrisonSJ,etal.PhaseIstudyofvenetoclaxplusdar- directedchimericantigenreceptorTcelltherapy,inpatientswithrelapsed/
atumumabanddexamethasone,withorwithoutbortezomib,inpatients refractorymultiplemyeloma.Blood2021;138(Suppl1):549.
withrelapsedorrefractorymultiplemyelomawithandwithoutt(11;14). 84. KnopS,StrakaC,HaenM,etal.Theefficacyandtoxicityofbendamus-
JClinOncol2021;39:3602–3612. tineinrecurrentmultiplemyelomaafterhigh-dosechemotherapy.Hae-
matologica2005;90:1287–1288.
62. CostaLJ,StadtmauerEA,MorganG,etal.Phase2studyofvenetoclax
pluscarfilzomibanddexamethasoneinpatientswithrelapsed/refractory 85. MichaelM,BrunsI,Bo€lkeE,etal.Bendamustineinpatientswithre-
multiplemyeloma.Blood2018;132(Suppl1):303. lapsedorrefractorymultiplemyeloma.EurJMedRes2010;15:13–19.
63. AbuelgasimKA,AlherzN,AlhejaziA,etal.Venetoclaxincombination 86. LenhardREJr,OkenMM,BarnesJM,etal.High-dosecyclophospha-
withcarfilzomibanddexamethasoneinrelapsed/refractorymultiplemy- mide.Aneffectivetreatmentforadvancedrefractorymultiplemyeloma.
elomaharboringt(11,14)(q13;q32):twocasereportsandareviewofthe
Cancer1984;53:1456–1460.
literature.JMedCaseReports2020;14:54. 87. OffidaniM,CorvattaL,MaracciL,etal.Efficacyandtolerabilityofbend-
64. Go€rgu€nG,CalabreseE,SoydanE,etal.Immunomodulatoryeffectsof amustine,bortezomibanddexamethasoneinpatientswithrelapsed-
lenalidomideandpomalidomideoninteractionoftumorandbonemar- refractorymultiplemyeloma:aphaseIIstudy.BloodCancerJ2013;3:
rowaccessorycellsinmultiplemyeloma.Blood2010;116:3227–3237. e162.
65. MiguelJS,WeiselK,MoreauP,etal.Pomalidomidepluslow-dose 88. GayF,Gu€ntherA,OffidaniM,etal.Carfilzomib,bendamustine,and
dexamethasoneversushigh-dosedexamethasonealoneforpatients dexamethasoneinpatientswithadvancedmultiplemyeloma:the
withrelapsedandrefractorymultiplemyeloma(MM-003):arando- EMN09phase1/2studyoftheEuropeanMyelomaNetwork.Cancer
mised,open-label,phase3trial.LancetOncol2013;14:1055–1066. 2021;127:3413–3421.
66. DimopoulosMA,PalumboA,WeiselK,etal.Safetyandefficacyinthe 89. LentzschS,O’SullivanA,KennedyRC,etal.Combinationofbenda-
stratus(MM-010)trial,asingle-armphase3bstudyevaluatingpomali- mustine,lenalidomide,anddexamethasone(BLD)inpatientswithre-
domide1low-dosedexamethasoneinpatientswithrefractoryorre- lapsedorrefractorymultiplemyelomaisfeasibleandhighlyeffective:
lapsedandrefractorymultiplemyeloma.Blood2014;124:80. resultsofphase1/2open-label,doseescalationstudy.Blood2012;
119:4608–4613.
67. LeleuX,AttalM,ArnulfB,etal.Pomalidomidepluslow-dosedexa-
methasoneisactiveandwelltoleratedinbortezomibandlenalidomide- 90. RivellGL,BrunsonCY,MilliganL,etal.Effectivenessandsafetyofhigh-
refractorymultiplemyeloma:IntergroupeFrancophoneduMye(cid:2)lome dosecyclophosphamideassalvagetherapyforhigh-riskmultiplemye-
2009-02.Blood2013;121:1968–1975. lomaandplasmacellleukemiarefractorytonewbiologicalagents.Am
JHematol2011;86:699–701.
68. LacyMQ,AllredJB,GertzMA,etal.Pomalidomidepluslow-dose
91. ShankBR,PrimeauxB,YeungEK,etal.Hyperfractionatedcyclophos-
dexamethasoneinmyelomarefractorytobothbortezomibandlenalido-
phamideanddexamethasonealoneorincombinationwithdaratumu-
mide:comparisonof2dosingstrategiesindual-refractorydisease.
Blood2011;118:2970–2975.
maband/orcarfilzomibforthetreatmentofrelapsedorrefractory
multiplemyeloma:asingle-centerretrospectiveanalysis.ClinLym-
69. WhiteD,ChenC,BaljevicM,etal.Oralselinexor,pomalidomide,and phomaMyelomaLeuk2023;23:279–290.
dexamethasone(XPd)atrecommendedphase2doseinrelapsedrefrac-
92. ChariA,VoglDT,GavriatopoulouM,etal.Oralselinexor-dexametha-
torymultiplemyeloma(MM).JClinOncol2021;39(Suppl):Abstract8018.
sonefortriple-classrefractorymultiplemyeloma.NEnglJMed2019;
70. LazzarinoM,CorsoA,BarbaranoL,etal.DCEP(dexamethasone,cyclo- 381:727–738.
phosphamide,etoposide,andcisplatin)isaneffectiveregimenforpe-
93. LonialS,LeeHC,BadrosA,etal.Belantamabmafodotinforrelapsed
ripheralbloodstemcellcollectioninmultiplemyeloma.BoneMarrow
Transplant2001;28:835–839. oo pr ere nf -r la ac bt eo lr ,y pm hau slt eip 2le stm udye yl .o Lm ana c( eD tR OEA ncM oM l2- 02 2): 0a ;2t 1w :2o 0-a 7r –m 2, 2r 1a .ndomised,
71. DadacaridouM,PapanicolaouX,MaltesasD,etal.Dexamethasone,
94. BerensonJR,LichtensteinA,PorterL,etal.Long-termpamidronate
cyclophosphamide,etoposideandcisplatin(DCEP)forrelapsedor
refractorymultiplemyelomapatients.JBUON2007;12:41–44. t er ve ea ntm ts.en Jt Co lif na Odv na cn oc le 1d 99m 8u ;1lt 6ip :5le 93m –y 6e 0l 2o .mapatientsreducesskeletal
72. GriffinPT,HoVQ,FulpW,etal.Acomparisonofsalvageinfusional 95. BerensonJR,LichtensteinA,PorterL,etal.Efficacyofpamidronatein
chemotherapyregimensforrecurrent/refractorymultiplemyeloma.
Cancer2015;121:3622–3630. r Ee nd gu lc Jin Mg es dke 1le 9t 9a 6l ;e 3v 3e 4n :4ts 88in –4p 9a 3ti .entswithadvancedmultiplemyeloma.N
73. LeeCK,BarlogieB,MunshiN,etal.DTPACE:aneffective,novelcom-
96. MajorP,LortholaryA,HonJ,etal.Zoledronicacidissuperiortopa-
binationchemotherapywiththalidomideforpreviouslytreatedpatients
withmyeloma.JClinOncol2003;21:2732–2739. midronateinthetreatmentofhypercalcemiaofmalignancy:apooled
analysisoftworandomized,controlledclinicaltrials.JClinOncol2001;
74. SrikanthM,DaviesFE,WuP,etal.Survivalandoutcomeofblastoid 19:558–567.
variantmyelomafollowingtreatmentwiththenovelthalidomidecon-
97. ZervasK,VerrouE,TeleioudisZ,etal.Incidence,riskfactorsandmanage-
tainingregimeDT-PACE.EurJHaematol2008;81:432–436.
mentofosteonecrosisofthejawinpatientswithmultiplemyeloma:a
75. BudaG,OrciuoloE,GalimbertiS,etal.VDTPACEassalvagetherapy single-centreexperiencein303patients.BrJHaematol2006;134:620–623.
forheavilypretreatedMMpatients.Blood2013;122:5377.
98. MorganGJ,DaviesFE,GregoryWM,etal.First-linetreatmentwithzole-
76. AndohS,ToganoT,ItoiS,etal.EfficacyandsafetyofVTD-PACEregi- dronicacidascomparedwithclodronicacidinmultiplemyeloma(MRC
meninrelapsedorrefractorymultiplemyeloma.ClinLymphomaMye- MyelomaIX):arandomisedcontrolledtrial.Lancet2010;376:1989–1999.
lomaLeuk2017;17(Suppl):e57. 99. JacksonGH,MorganGJ,DaviesFE,etal.Osteonecrosisofthejawandre-
77. LakshmanA,SinghPP,RajkumarSV,etal.EfficacyofVDTPACE-like nalsafetyinpatientswithnewlydiagnosedmultiplemyeloma:MedicalRe-
regimensintreatmentofrelapsed/refractorymultiplemyeloma.AmJ searchCouncilMyelomaIXStudyresults.BrJHaematol2014;166:109–117.
Hematol2018;93:179–186.
100. MorganGJ,DaviesFE,GregoryWM,etal.Long-termfollow-upof
78. LesokhinAM,TomassonMH,ArnulfB,etal.Elranatamabinrelapsedor MRCMyelomaIXtrial:Survivaloutcomeswithbisphosphonateandtha-
refractorymultiplemyeloma:phase2MagnetisMM-3trialresults.Nat lidomidetreatment.ClinCancerRes2013;19:6030–6038.
Med2023;29:2259–2267.
101. MhaskarR,RedzepovicJ,WheatleyK,etal.Bisphosphonatesinmulti-
79. ChariA,MinnemaMC,BerdejaJG,etal.Talquetamab,aT-cell–redirecting plemyeloma:anetworkmeta-analysis.CochraneDatabaseSystRev
GPRC5Dbispecificantibodyformultiplemyeloma.NEnglJMed2022; 2012;5:CD003188.
387:2232–2244.
102. HimelsteinAL,FosterJC,KhatcheressianJL,etal.Effectoflonger-interval
80. MoreauP,GarfallAL,vandeDonkNW,etal.Teclistamabinrelapsed vsstandarddosingofzoledronicacidonskeletaleventsinpatientswith
orrefractorymultiplemyeloma.NEnglJMed2022;387:495–505. bonemetastases:arandomizedclinicaltrial.JAMA2017;317:48–58.
JNCCN.org | Volume21 Issue12 | December2023 1299

NCCNGUIDELINES® MultipleMyeloma, Version2.2024
103. RajeN,TerposE,WillenbacherW,etal.Denosumabversuszoledronic withconcurrentsystemictreatment.Cancers(Basel)2022;
acidinbonediseasetreatmentofnewlydiagnosedmultiplemyeloma: 14:2273.
aninternational,double-blind,double-dummy,randomised,controlled, 108. ElhammaliA,AminiB,LudmirEB,etal.Newparadigmforradiationin
phase3study.LancetOncol2018;19:370–381.
multiplemyeloma:loweryeteffectivedosetoavoidradiationtoxicity.
104. MajorPP,ColemanRE.Zoledronicacidinthetreatmentofhypercalce- Haematologica2020;105:e355–357.
miaofmalignancy:resultsoftheinternationalclinicaldevelopmentpro-
gram.SeminOncol2001;28(Suppl6):17–24. 109. LindsleyH,TellerD,NoonanB,etal.Hyperviscositysyndrome
inmultiplemyeloma.Areversible,concentration-dependent
105. PecherstorferM,SteinhauerEU,RizzoliR,etal.Efficacyandsafetyof
aggregationofthemyelomaprotein.AmJMed1973;54:
ibandronateinthetreatmentofhypercalcemiaofmalignancy:aran- 682–688.
domizedmulticentriccomparisontopamidronate.SupportCareCancer
2003;11:539–547. 110. LudwigH,FritzE,KotzmannH,etal.Erythropoietintreatmentof
106. ResendeSalgadoL,WangS,AdlerA,etal.Thesafetyprofileofconcur- anemiaassociatedwithmultiplemyeloma.NEnglJMed1990;322:
renttherapyformultiplemyelomainthemodernera.AdvRadiatOncol
1693–1699.
2018;4:112–117. 111. OsterborgA,BoogaertsMA,CiminoR,etal.Recombinanthuman
107. GueriniAE,TucciA,AlongiF,etal.RRMyeloPOINT:aretrospec- erythropoietinintransfusion-dependentanemicpatientswithmultiple
tivesingle-centerstudyassessingtheroleofradiotherapyin myelomaandnon-Hodgkin’slymphoma—arandomizedmulticenter
themanagementofmultiplemyelomaandpossibleinteractions study.Blood1996;87:2675–2682.
1300 ©JNCCN—JournaloftheNationalComprehensiveCancerNetwork | Volume21 Issue12 | December2023

MultipleMyeloma,Version2.2024 NCCNGUIDELINES®
IndividualDisclosuresfortheNCCNMultipleMyelomaPanel
ScientificAdvisoryBoards,Consultant, PromotionalAdvisoryBoards,Consultant,or
PanelMember ClinicalResearchSupport/DataSafetyMonitoringBoard orExpertWitness SpeakersBureau Specialties
KehindeAdekola,MD,MSCI BloodandMarrowTransplantClinicalTrialsNetwork None None Hematology;Medicaloncology
LarryD.AndersonJr,MD,PhD AbbVie,Inc.;BristolMyersSquibb;Cellectar;GSK;Janssen AbbVie,Inc.;BeiGene;BristolMyersSquibb;Celgene None Hematology;Medicaloncology
PharmaceuticaProducts,LP;Prothena Corporation;Cellectar;GSK;JanssenPharmaceutica
Products,LP;Prothena;sanofi-aventisU.S.
MuhamedBaljevic,MD None None BristolMyersSquibb;CardinalHealth; Medicaloncology;Hematology;Internal
CurioScience;JanssenBiotech,Inc.;Karyopharm medicine;Bonemarrowtransplantation
Therapeutics;Parexel;Sanofi-Genzyme;Targeted
Oncology
RachidBaz,MD AbbVie,Inc.;Arvinas;BristolMyersSquibb;Daiichi-Sankyo BristolMyersSquibb;GSK AdventHealth;CurioScience;Hikma Medicaloncology;Hematology
Co.;JanssenPharmaceuticaProducts,LP;Karyopharm
Therapeutics;MarkerTherapeutics;PfizerInc.;Pionyr
Immunotherapeutics;QuantumLeapHealthcare
Collaborative;RegeneronPharmactcls;SeaGen;Zymeworks
NatalieS.Callander,MD None None None Hematology;Bonemarrowtransplantation
EricaCampagnaro,MD None None None Hematology
JorgeJ.Castillo,MD AbbVie,Inc.;AstraZenecaPharmaceuticalsLP;BeiGene; AbbVie,Inc.;BeiGene;Cellectar;Janssen None Hematology
Cellectar;EliLillyandCompany;Pharmacyclics;TG PharmaceuticaProducts,LP;KitePharma;
Therapeutics Pharmacyclics
CaitlinCostello,MD None CelgeneCorporation;JanssenPharmaceutica None Medicaloncology;Hematology;Bone
Products,LP;PfizerInc.;RegeneronPharmactcls; marrowtransplantation
TakedaPharmaceuticalsNorthAmerica,Inc.
ChristopherD’Angelo,MD BeiGene;BristolMyersSquibb;FateTherapeutics AbbVie,Inc.;BristolMyersSquibb;OnoPharmaUSA; None Medicaloncology;Hematology
SeaGen
SrinivasDevarakonda,MD None None None Hematology;Medicaloncology
NouraElsedawy,MDa GSK None None Medicaloncology
AlfredGarfall,MD CRISPRTherapeutics;JanssenPharmaceuticaProducts,LP; BristolMyersSquibb;GSK;JanssenPharmaceutica None Hematology
NovartisPharmaceuticalsCorporation;TmunityTherapeutic Products,LP;NovartisPharmaceuticalsCorporation
KellyGodby,MD None None None Medicaloncology
JensHillengass,MD,PhD AmgenInc.;BristolMyersSquibb;FateTherapeutics;Gilead AptitudeHealth;GSK;Intellisphere;Janssen None Hematology
Sciences,Inc.;GSK;Harpoon;IGMBiosciences,Inc.;Janssen PharmaceuticaProducts,LP;Oncopeptides;Prothena;
PharmaceuticaProducts,LP;PfizerInc.;Prothena;sanofi- sanofi-aventisU.S.;Skyline
aventisU.S.
LeonaHolmberg,MD,PhDa BristolMyersSquibb;ITeos;Merck&Co.,Inc.;sanofi-aventis BiolineRX None Bonemarrowtransplantation;Hematology
U.S.;TakedaPharmaceuticalsNorthAmerica,Inc.
MyoHtut,MD CelgeneCorporation;JanssenPharmaceuticaProducts,LP None None Hematology;Internalmedicine
CarolAnnHuff,MD Glenmark/Ichnos;Prothena sanofi-aventisU.S. None Medicaloncology;Hematology
MalinHultcrantz,MD,PhD AbbVie,Inc.;BeiGene;Daiichi-SankyoCo.;GSK;Springworks BristolMyersSquibb;GSK None Hematology;Medicaloncology
YubinKang,MD KaryopharmTherapeutics;TakedaPharmaceuticalsNorth sanofi-aventisU.S. None Hematology;Medicaloncology;Bone
America,Inc. marrowtransplantation
ShajiK.Kumar,MD AbbVie,Inc.;Allogene;Arcellx;BristolMyersSquibb; AbbVie,Inc.;BristolMyersSquibb;GSK;PfizerInc.; None Hematology;Bonemarrowtransplantation
Carsgen;GSK;JanssenPharmaceuticaProducts,LP;Roche RegeneronPharmaceuticals,Inc.;RocheLaboratories,
Laboratories,Inc.;TakedaPharmaceuticalsNorthAmerica, Inc.;sanofi-aventisU.S.;TakedaPharmaceuticalsNorth
Inc. America,Inc.
SarahLarson,MD AbbVie,Inc.;Allogene;BristolMyersSquibb;Celgene 1200Pharma;TORLBiotherapeutics Oncovalent Medicaloncology
Corporation;JanssenPharmaceuticaProducts,LP;Juno
Therapeutics,Inc.;PfizerInc.;sanofi-aventisU.S.
HansC.Lee,MD AllogeneTherapeutics;AmgenInc.;CelgeneCorporation; BristolMyersSquibb;CelgeneCorporation; None Medicaloncology;Hematology
JanssenPharmaceuticaProducts,LP;Regeneron Genentech,Inc.;GSK;JanssenPharmaceutica
Pharmaceuticals,Inc.;TakedaPharmaceuticalsNorth Products,LP;RegeneronPharmactcls;sanofi-aventis
America,Inc. U.S.;TakedaPharmaceuticalsNorthAmerica,Inc.
MichaelaLiedtke,MD AbbVie,Inc.;Allogene;BristolMyersSquibb;Caelum;Gilead BristolMyersSquibb;JanssenPharmaceutica None Hematology
Sciences,Inc.;JanssenPharmaceuticaProducts,LP;SeaGen Products,LP;KitePharma
ThomasMartin,MD AmgenInc.;BristolMyersSquibb;JanssenPharmaceutica EliLillyandCompany;GSK;PfizerInc. None Hematology
Products,LP;sanofi-aventisU.S.
JamesOmel,MD None None None Patientadvocacy
TimothyRobinson,MD,PhD None KitePharma None Radiationoncology
AaronRosenberg,MD Biomea;GSK;KangpuBiopharmaceuticals;Sorento;Takeda KangpuBiopharmaceuticals None Medicaloncology;Hematology;Bone
PharmaceuticalsNorthAmerica,Inc. marrowtransplantation
DouglasSborov,MD,MSc AbbVie,Inc.;AmgenInc.;Arcellx;BeiGene;Biotin;Bristol AbbVie,Inc.;Arcellx;AstraZenecaPharmaceuticalsLP; None Medicaloncology;Hematology;Internal
MyersSquibb;Caribou;GileadSciences,Inc.;GSK;Janssen GSK;JanssenPharmaceuticaProducts,LP;PfizerInc.; medicine;Bonemarrowtransplantation
PharmaceuticaProducts,LP;KaryopharmTherapeutics;Pfizer sanofi-aventisU.S.
Inc.;RocheLaboratories,Inc.
MarkA.Schroeder,MD IchnosSciencesSA;IncyteCorporation;Janssen None NovoNordisk;GSK Medicaloncology;Hematology
PharmaceuticaProducts,LP;KuraOncology;Marker
Therapeutics;Sorrento;TakedaPharmaceuticalsNorth
America,Inc.
DanielSherbenou,MD,PhD KaryopharmTherapeutics;PfizerInc.;sanofi-aventisU.S. None None Medicaloncology
AttayaSuvannasankha,MD BristolMyersSquibb;GSK;JanssenPharmaceuticaProducts, BristolMyersSquibb;GSK;JanssenPharmaceutica None Medicaloncology;Hematology
LP;RegeneronPharmactcls;SUTROBiopharma,Inc. Products,LP
JasonValent,MD AbbVie,Inc.;AlexionPharmaceuticals,Inc.;Allogene None None Medicaloncology;Hematology
therapeutics;AmgenInc.;BristolMyersSquibb;GSK;
JanssenPharmaceuticaProducts,LP;PfizerInc.;
Pharmacyclics;ProthenaBiosciences
AsyaNinaVarshavsky-Yanovsky, AbbVie,Inc.;BristolMyersSquibb;GileadSciences,Inc.; BristolMyersSquibb;GSK;JanssenPharmaceutica None Medicaloncology;Hematology
MD,PhD PfizerInc. Products,LP;PfizerInc.
TheNCCNGuidelinesStaffhavenoconflictstodisclose.
aThefollowingindividualshavedisclosuresrelatingtoemployment/governingboard,patent,equity,orroyalty:
NouraElsedawy,MD:Vyriad.
LeonaHolmberg,MD,PhD:Up-To-Date.
JNCCN.org | Volume21 Issue12 | December2023 1301

